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1. AIM OF THE STUDY 
 
Down syndrome (DS), caused by trisomy of human chromosome 21 (HSA21), is 
one of the most common genetic causes of mental retardation, occurring in one 
out 800-1000 live births (Hayes and Batshaw 1993; Roizen and Patterson 2003; 
Shin, Besser et al. 2009). Although a wide range of variable traits characterizes 
Dow syndrome, intellectual disability is the unavoidable hallmark of the 
pathology, with a heavy impact on public health. Mental retardation in DS is 
likely due to widespread brain hypoplasia and hypocellularity that start to be 
present from early developmental stages and are retained in adulthood. Recent 
evidence from our laboratory shows that the fetal DS brain is characterized by 
severe proliferation impairment that involves numerous brain regions 
(Contestabile, Fila et al. 2007; Guidi, Bonasoni et al. 2008; Guidi, Ciani et al. 
2011). These findings clearly indicate that neurogenesis impairment is a key 
determinant underlying brain malfunctioning in DS.  
 
Mouse models that mimic human pathologies as closely as possible are becoming 
invaluable tools because they can be exploited to identify the mechanisms 
underpinning a given pathology and to examine the outcome of targeted therapies. 
Various mouse models for DS are now available but the Ts65Dn mouse is one of 
the most widely used because it displays several neuroanatomical and behavioral 
defects that closely recapitulate the human condition (Reeves, Gearhart et al. 
1986). In the Ts65Dn mouse neurogenesis is severely impaired in the embryonic 
ventricular zone and hippocampus (Chakrabarti, Galdzicki et al. 2007) and in the 
hippocampus, cerebellum and subventricolar zone (SVZ) of neonate and adult 
mice (Baxter, Moran et al. 2000; Contestabile, Fila et al. 2007; Contestabile, Fila 
et al. 2009). This evidence validates the use of the Ts65Dn mouse model to get 
insight into the mechanisms underlying proliferation impairment in DS. 
 
The mechanisms by which trisomy 21 interferes with brain development are 
still largely unknown. It has been recently shown that the reduced proliferation 
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of cerebellar granule cell precursors from Ts65Dn mice is related to an attenuated 
response to sonic hedgehog (Shh) (Roper, Baxter et al. 2006), a potent mitogen 
that controls cell division during brain development (Ishibashi, Saitsu et al. 2005). 
The wide brain expression of the Shh pathway (Ishibashi, Saitsu et al. 2005; 
Arsic, Beasley et al. 2007), suggests that it may exert a widespread role in the 
regulation of neural precursor proliferation in different brain neurogenic zones. If 
so, a generalized attenuation of the response to Shh might account for the 
widespread neurogenesis impairment that characterizes the trisomic brain.  
 
Although in vivo models reflect in a more realistic fashion the environment of the 
diseased brain, in view of the complexity of the mechanisms underlying 
neurological diseases, simplified in vitro approaches are often essential tools to 
better dissect the molecular mechanisms that take part in the pathology.  
The overall goal of the present study was to create an in vitro model suitable 
to understand the mechanism/s underlying neurogenesis impairment in DS. 
The specific goals were to: 
i) establish whether cultures of neural precursor cells (NPCs) from Ts65Dn 
mice exhibit the same proliferation defects as the in vivo condition; 
ii) establish whether NPCs exhibit a defective response to Shh, similarly to 
cerebellar granule cell precursors;  
iii) dissect the molecular mechanisms that underlie deregulation of the Shh 
pathway and, consequently, the proliferation impairment of trisomic NPCs. 
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2. INTRODUCTION 
 
2.1 DOWN SYNDROME (DS) 
2.1.1 History of DS 
The history of the discovery and characterization of the DS has been summerized 
in very fine details by Pierre L. Roubertoux and Bernard Kerdelhué in a review of 
2006 (Roubertoux, Bichler et al. 2006). They describe that in 1838, Jean-Etienne-
Dominique Esquirol, specialized in ‘‘mental insanity’’, published the first 
handbook of psychiatry, entitled “Des maladies mentales considérées Les sous les 
rapports médical, hygiénique et médico-légal” [Mental Disease: medical, 
health/hygiene and medical-legal considerations] (Esquirol 1838). Esquirol, who 
had previously published “Des Passions considerées comme causes, symptomes et 
moyens curatifs de l’aliénation mentale” [The passions considered as causes, 
symptoms and means of curing cases of insanity] (Esquirol 1805), had also set up 
a course on ‘‘mental disorders’’ in  1811, at Salpétrière Hospital in Paris, where 
he was an ‘‘ordinary physician’’ working under Pinel. A large section of the 1838 
book was devoted to ‘‘Idiocy’’, covering what is now referred to as ‘‘mental 
deficiency’’, ‘‘mental retardation’’ or ‘‘feeble mindedness’’. Esquirol described a 
particular category of patient characterized by oblique eye fissures, epicanthic 
eye-folds, a flat nasal bridge and protruding tongue. Esquirol noted their short, 
stocky stature with virtually no neck, with malformed limbs and mental 
retardation. The description clearly tallies with the modern symptomatology of 
trisomy 21. Eight years later, Edouard Séguin (1846) took up this description of 
the symptomatological group, adding a detailed description of the small nose and 
open mouth; he described the morphology of the tongue, that was thick and 
cracked, and the susceptibility of the lungs and integuments to infection. In two 
later papers, first published in English (Séguin 1856; Seguin 1866), Séguin wrote 
that in spite of ‘‘profound idiocy’’, these ‘‘good kids’’ had language and were 
able to gain some basic knowledge. He described the mental pathology reported 
by Esquirol in greater detail and named it ‘‘furfuraceous cretinism’’ because of 
the bran-like appearance of the skin of trisomic 21 persons. 
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A classification based on ‘‘races’’ devised by the German Blumenbach was 
popular in England in the mid-nineteenth century and featured five main groups: 
Mongolians, Aztecs, Caucasians, Malayans and Ethiopians. The British alienist, 
John Langdon Haydon Down, classified patients in the mental hospital where he 
was working and assigned them to these ethnic groups. ‘‘A very large number of 
congenital idiots are typical Mongols. So marked is this that, when placed side by 
side, it is difficult to believe the specimens compared are not children of the same 
parents.’’ (Down 1866). The description of what was later referred to as trisomy 
21 was made using Down’s obsolete racial framework. ‘‘The Mongolian type of 
idiocy occurs in more than ten per cent of the cases which are presented to me. 
They are always congenital idiots and never result from accidents after uterine 
life. They are, for the most part, instances of degeneracy arising from tuberculosis 
in the parents. They have considerable power of imitation, even bordering on 
being mimics. They are humorous and a lively sense of the ridiculous often colors 
their mimicry. This faculty of imitation can be cultivated to a very great extent 
and a practical direction given to the results obtained. They are usually able to 
speak; the speech is thick and indistinct, but may be improved very greatly by a 
well-directed scheme of tongue gymnastics. The coordinating faculty is abnormal, 
but not so defective that it cannot be strengthened. By systematic training, 
considerable manipulative power may be obtained. The circulation is feeble and 
however much advance is made intellectually in the summer, some amount of 
retrogression may be expected in the winter. Mental and physical capabilities are, 
in fact, directly as the temperature. The improvement which training effects in 
them is greatly in excess of what would be predicted if one did not know the 
characteristics of the type. The life expectancy, however, is far below the average, 
and the tendency is to tuberculosis which I believe to be the hereditary origin of 
the degeneracy.’’ The term ‘‘mongolism’’ was adopted from Down’s 
classification and was in common usage by the late nineteenth century, but as it 
refers to clearly non-scientific etiology, it has been discarded. The term 
‘‘mongolism’’ was gradually seen as an embarrassment and in 1961 the term 
‘‘Down’s syndrome’’ was suggested by Allen (as reported by Ward, 1998).  
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It was not until 1959 that Dr. Jerome Lejeune, a French physician, made the 
discovery that Down’s Syndrome was the result of a chromosomal abnormality. 
His research led him to the fact that the cells of people with Down’s Syndrome 
had 47 chromosomes instead of 46. Dr. Jerome Lejeune identified in subjects with 
Down’s syndrome a triplication of the chromosome 21. In this way, the term 
‘‘trisomy 21’’ (TRS21) was introduced. 
 
2.1.2 Epidemiology 
In the world, 1 of every 800-1000 live births has trisomy 21 (Winter, Ostrovsky et 
al. 2000). Worldwide about 220,000 infants with trisomy 21 are born each year 
with phenotypes collectively referred to as DS (Christianson, Howson et al. 
2006). The prevalence of DS does not correlate to geographic location, socio-
economic level or ethnicity (Lejeune 1959; Czarnetzki, Blin et al. 2003). The 
increasing probability of having a DS child correlates to the increasing age of the 
mother, as was first observed by Penrose (Penrose 1951). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2.1.3 Etiology 
MATERNAL AGE INCIDENCE 
< 30 years old 1 of 1500  
30-34 years old 1 of 580  
35-39 years old 1 of 280 
40-44 years old 1 of 70  
> 45 years old 1 of 38  
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Genomic aneuploidy, defined as an abnormal number of copies of a 
genomic region, is a common cause of human genetic disorders. Classically, the 
term aneuploidy was restricted to the presence of supernumerary copies of whole 
chromosomes (trisomy), or absence of chromosomes (monosomy), but now we 
can extend this definition to include deletions or duplications of subchromosomal 
regions (Antonarakis, Lyle et al. 2004). Trisomy 21 is a model of all human 
disorders that are the result of supernumerary copies of a genomic region 
(Antonarakis, Lyle et al. 2004). 
Non-disjunction 
Several hypotheses were formulated before Lejeune discovered the path to the 
genetic/chromosomal origin of what was then called ‘‘Mongolism’’, with an extra 
copy of one chromosome but two other advances were needed before the 
discovery could be made. Cytogenetic studies were needed: 1) to determine the 
exact number of human chromosomes; 2) for the individual cytological 
characterization of each chromosome. Tijo and Levan (Tijo 1956) established that 
the human genome has 46 chromosomes. Two years later, in 1958, Lejeune 
reported that a patient had 47 instead of 46 chromosomes, the hypothesis being 
either a translocation on chromosome 4 or an extra chromosome present. Lejeune 
confirmed the finding of an extra chromosome 21 in two patients and went on to 
report an extra chromosome 21 in 9 ‘‘mongoloid’’ patients (Lejeune 1959). The 
year after this discovery, the observation of a triple chromosome 21 in patients 
with the same clinical diagnosis was reproduced by other independent groups 
(Fig.1).  
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Figura 1 
Figure 1 Karyotype for trisomy Down syndrome. G-banded 
karyotype of a trisomy 21 female, showing three copies of human 
chromosome 21 (HSA21).  
Figure 2: Fluorescent in situ hybridization (FISH) of interphase 
nuclei of a trisomy 21 fetus. In red the trisomic chromosome  21. 
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More recent analyses using molecular tools (Fig. 2) have confirmed that in DS, 
95% of all cases are caused by full trisomy of chromosome 21, whereby all 
HSA21 genes are present in 3 copies, resulting from a chromosomal non-
disjunction. One cell has two HSA21 instead of one, so the resulting fertilized egg 
has three HSA21 chromosomes. If a sperm or egg with an abnormal number of 
chromosomes merges with a normal mate, the resulting fertilized egg will have an 
abnormal number of chromosomes. Hence the scientific name, trisomy 21. Recent 
research has shown that in these cases, approximately 90% of the abnormal cells 
are eggs (Antonarakis 1996). The cause of the non-disjunction error remains still 
unknown. Research is currently aimed at trying to determine the cause and timing 
of the non-disjunction events.  
Robertsonian Translocation 
Three to four percent of all cases of trisomy 21 are due to Robertsonian 
Translocation. In this case, two breaks occur in separate chromosomes, usually the 
14th and 21st chromosomes. There is a rearrangement of the genetic material so 
that some of the 14th chromosome is replaced by extra 21st chromosome. So 
while the number of chromosomes remains normal, there is a triplication of the 
21st chromosome material. Translocations resulting in trisomy 21 may be 
inherited.  
Mosaicism 
The remainder of cases of trisomy 21 is due to mosaicism. In genetics, a mosaic 
or mosaicism denotes the presence of two or more populations of cells with 
different genotypes in one individual who has developed from a single fertilized 
egg. Mosaicism may result from a mutation during development which is 
propagated to only a subset of the adult cells.  
 
2.1.4 Somatic traits and clinical features  
Children with DS exhibit chatacteristic and peculiar physical traits: 
• Short stature : children with DS usually have slow growth rate, and in 
adulthood their height is lower than average; 
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• Low muscle tone : children may have less muscle strength than other 
children of the same age; 
• Short neck, thick with fat and excess skin : usually this feature becomes 
less obvious as the children grow; 
• Short and stocky limbs, some children may have a wider space between 
the thumb and second finger of the foot; 
• One fold in the central part of the palm : it is called the simian line. 
Facial features. They show typical facial features which include, for example, 
ears with modified form, usually small and with a low placement (Fig. 3 E). They 
present, also, abnormal mouth and tongue, with mouth often open (Fig. 3 F). It is 
typical to find children with exfoliative glossitis and tongue with scrotal 
appearance (in adolescents and adults). Furthermore, it is frequrent 
pseudomacroglossia (Fig. 3 F). It is very characteristic a flattened nasal bridge and 
this flat nose portion, located between the two eyes (nasal bridge), is frequently 
clogged (Fig. 3A). There are, often on their faces Brushfield’s spots. They are 
colored spots on the iris, without affecting the sight. Moreover, malformation of 
the teeth are very frequent: baby teeth may grow later and in an unusual way with, 
often, agenesis of lateral incisors. 
Skeleton and skin features. Besides the short arms, they exhibit a finger 
clinodactyly of the fifth finger with a single flexion crease, flat foot and increased 
space between first toe and second toe.Tipically their skin is dried with xerosis. 
There are recurent cases, also, of hyperkeratotic lesions, alopecia, vitiligo, 
foliculitis and skin infections. 
Psychomotor retardation. Hypotonia occurs soon at birth. 
 
Congenital abnormalities associated with DS. Although DS is usually linked to 
intellectual disability, the morbidity from other associated congenital 
abnormalities is considerable. Many infants with DS have co-occurring congenital 
malformations (Fig. 4) requiring intensive surgical and medical management. To 
anticipate the care needed by these infants, providers and parents require accurate 
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information about birth defects that may be present. With this purpose in mind, 
many articles use different datasets to identify the rate at which structural birth 
defects are identified among children with DS. Overall, about one in five live born 
children with DS dies before the age of 5 years, and about two of five survivors 
have major health problems in addition to mental retardation in early childhood 
(Noble 1998).  
Congenital heart diseases were the most frequently documented birth defects in 
live born infants with DS and approximately 46% of infants with DS were born 
with one or more heart defects. The three most common types of congenital heart 
defects were atrioventricular canal defects (45%), ventricular septal defects (35%) 
and patent ductus ateriousus (Roizen and Patterson 2003). The atrioventricular 
canal defect is the most serious of these defects. In the normal formation of the 
heart the endocardial cushions grow toward each other and leave openings 
between the atria and the ventricles, where the mitral and tricuspid valves form. 
The atrioventricular canal defect is caused by a failure of this process and results 
in the formation of a single valve structure with a septal defect above and below 
it. Survival can be improved with surgery, but the prognosis in children with these 
abnormalities is still poor because of the increased risk of heart failure. The 
ventricular septal defect, a defect in the ventricular septum, which divides the left 
and the right ventricles, may require surgery, though about 15% close 
spontaneously. The patent ductus is a congenital defect wherein a neonate's ductus 
arteriousus, the shunt connecting the pulmonary artery to the aortic arch, fail to 
close after birth. It is not a serious abnormality and can be corrected by a 
relatively simple surgical procedure. Assessment of all newborns with DS with an 
echocardiogram is the standard recommendation. Symptoms of serious heart 
disease may be absent or hidden due to the tendency of children with DS to 
develop pulmonary vascular resistance. Adolescents and young adults with no 
known intracardiac disease can develop mitral valve prolapse (46%) and aortic 
regurgitation (17%), and most experts recommend assessment also of adult 
patients.  
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After the co-occurring heart abnormalities, the second most common 
malformations in children with DS are those of the gastrointestinal tract (11%) 
(Fig. 4) like duodenal atresia, Hirschsprung's disease and tracheo-oesphaegal 
fistula (Noble 1998). Duodenal atresia is the congenital absence or complete 
closure of a portion of the lumen of the duodenum. Approximately 8% of all 
infants with DS show this disease and it’s 300 times more common in individuals 
Figure 3: Down syndrome main features. A) Typical face, B) eye of a DS 
subject. Note the oblique eye fissures and the epicanthic eye-folds , C)-D) hand 
(C) and feet (D). Note the shortened, incurved fifth fingers. E) small ear, F) 
protruding tongue. 
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affected than in normal newborns. The Hirschsprung's disease or aganglionic 
megacolon, involves an enlargement of the colon by bowel obstruction resulting 
from absence of the enteric innervation in this section of bowel.  
Other congenital abnormalities have been reported in association with DS: 
malformations in the genitourinary system (6%), including stenosis or atresia of 
the urinary tract at any location, malformations of the abdominal wall, limb 
defects (9%) (reduction of both the lower and upper extremities) and congenital 
cataract (1%) (Noble 1998). 
 
 
2.1.5 Behavioural defects in DS 
Mental retardation remains the invariable hallmark of DS and its more 
Figure 4: Variable traits and clinical features in Down syndrome. 
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invalidating pathological aspect with a hard impact in the public health. In DS 
patients, the average IQ score is around 50, with individual values ranging from 
30 to 70. (Chapman and Hesketh 2000; Vicari 2006). The early infancy is 
characterized by a delayed cognitive development, leading to mild-to-moderate 
mental retardation. The IQ declines from early in the first year to late childhood 
(Brown, Greer et al. 1990; Hodapp, Dykens et al. 1990) and the decline in 
cognitive performance that occurs in the adult DS patients has been considered as 
the consequence of accelerated aging (Devenny, Silverman et al. 1996; Lott and 
Head 2005). Mental retardation in DS is characterized by major neurological 
dysfunctions in the short- and long-term memory (Carlesimo, Marotta et al. 1997; 
Nadel 2003). It has been also demonstrated a decline with age on measures of 
long-term memory, providing behavioral evidence of hippocampal dysfunction by 
adolescence (Carlesimo, Marotta et al. 1997), consistent with the structural 
magnetic resonance imaging (MRI) finding of reduced hippocampal volumes in 
adolescents with DS (Jernigan, Bellugi et al. 1993; Pennington, Moon et al. 
2003). There is also evidence for impairment of prefrontal cortex and cerebellar 
function (Nadel 2003) and speech and articulation are also particularly affected. 
The lower performances of DS in linguistic tasks may be partially explained in 
terms of impairment of the frontocerebellar structures involved in articulation and 
verbal working memory (Fabbro, Libera et al. 2002). Moreover, learning can be 
complicated by avoidance strategies when faced with cognitive challenges 
(Epstein 1995). Psychometric examinations of DS patients have shown that not all 
skills are affected in all persons or to the same extent. (Crnic 2002; Krinsky-
McHale, Devenny et al. 2002; Brown 2003; Clark and Wilson 2003; Pennington, 
Moon et al. 2003; Vicari 2006). Although all domains of development follow the 
usual sequence, a deficiency in language production relative to other areas of 
development often causes substantial impairment (Chapman, Seung et al. 1998). 
Children with DS have more behavioral and psychiatric problems than in other 
children, but fewer than in other individuals with mental retardation. In adult age, 
DS patients can have a similar prevalence of psychiatric problems to other people 
with intellectual disability. A raised frequency of psychiatric problems is also 
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related to the increased prevalence of depression in people with DS. However, 
they seem protected from some psychiatric disorders such as personality disorder, 
schizophrenia and anxiety. (Collacott, Cooper et al. 1998). Elsewhere, DS 
children show continuous but gradual improvement in mental age throughout 
childhood; intelligence quotients generally decline from early in the first year to 
late childhood (Hodapp, Dykens et al. 1990). Consequently, early implementation 
of special education programs results in improved cognitiveabilities in DS 
individuals. (Chapman, Seung et al. 1998). 
By age 40 years, there is a ubiquitous occurrence of plaques and tangles 
suggestive of Alzheimer disease (AD), with an increase in dementia. The earliest 
manifestations of dementia in DS appear to reflect frontal lobe dysfunction with 
changes in sociability, emotional-based language, and depressive symptoms. 
However, physical–chemical dating of amyloid has suggested that it is first 
deposited in the frontal and entorhinal cortices. The amyloid burden in DS is, in 
part, related to increases in the expression of the amyloid precursor protein gene, 
but other factors are likely involved. Oxidative stress secondary to critical-
regionmutations in mitochondrial DNA is associated with an increased brain 
concentration of oxidized β-amyloid.  
 
2.1.6 Neuroanatomy of DS 
The DS brain is characterized by numerous structural alterations that start to be 
present from early developmental stages and are retained in adulthood. Reduced 
thickness of cortical layers, diffuse hypocellularity, and astrocytic hypertrophy are 
a characteristic feature of the DS brain (Bartesaghi, Guidi et al. 2011). Autopsy 
data on the neuroanatomy of DS have been complemented by increasing studies 
from in vivo structural imaging using computer assisted tomography, voxel-based 
morphometry and to a larger extent MRI. The brain of DS subjects is 
characterized by several postmortem macroscopic features that are related to pre- 
and post-natal abnormalities in synaptogenesis leading to retardation of brain 
growth (Schmidt-Sidor, Wisniewski et al. 1990), such as lower brain weight and 
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brachycephaly, with a small cerebellum, frontal and temporal lobes reduced 
number and depth of the cerebral sulci, and a narrow superior temporal gyrus. 
(Coyle, Oster-Granite et al. 1986; Schmidt-Sidor, Wisniewski et al. 1990; Becker, 
Mito et al. 1991). MRI studies show regional brain abnormalities in young and 
non-demented adult DS subjects, consistent with postmortem data. Overall, brain 
volume is reduced in DS subjects, including cerebellar and cerebral gray and 
white matter. (Schapiro, Haxby et al. 1992; Pinter, Eliez et al. 2001). In 
particular, the reduced cerebellum shows a decreased volume of lobules VI–VIII 
(Avraham, Sugarman et al. 1991; Jernigan, Bellugi et al. 1993; Raz, Torres et al. 
1995). In the temporal neocortex of fetuses with DS the emergence of lamination 
is both delayed and disorganized (Golden and Hyman 1994), total neuron number 
is reduced in the hippocampal dentate gyrus (DG), hippocampus and 
parahippocampal gyrus (Guidi, Bonasoni et al. 2008) and the cellular layers of the 
cerebellum are characterized by prominent hypocellularity and reduced thickness 
(Guidi, Ciani et al.). 
In contrast, an increased volume is found in other brain areas, such as ventricles 
(Kesslak, Nagata et al. 1994; Pearlson, Breiter et al. 1998¸ Ikeda, 2002 #630; 
Schimmel, Hammerman et al. 2006) parahippocampal gyrus after adjustment for 
overall brain volume (Kesslak, Nagata et al. 1994; Raz, Torres et al. 1995; 
Teipel, Schapiro et al. 2003; Teipel and Hampel 2006) temporal, parietal and 
posterior cortex, lenticular nucleus, thalamus and hypothalamus (Jernigan, 
Bellugi et al. 1993; Pinter, Eliez et al. 2001), while the occipital lobe and superior 
temporal gyrus do not show volume changes after adjustment for overall brain 
volume (Frangou, Aylward et al. 1997; Pinter, Eliez et al. 2001). The second 
phase of cortical development and the emergence of lamination are delayed and 
disorganized in fetal DS brain. In addition to the known effects of the 
hippocampal formation in spatial memory, the altered cortical layer and 
cerebellum also may participate to cognitive and behavioral phenotypes in DS 
(Funahashi, Takeda et al. 2004). 
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2.1.7 Causes of brain hypotrophy in DS 
The widespread hypoplasia of the DS brain is considered to be the main cause of 
mental retardation. Several lines of evidence show that two major 
determinants underlie brain hypotrophy in DS are neurogenesis reduction 
and dendritic hypotrophy (Coyle, Oster-Granite et al. 1986; Becker, Mito et al. 
1991). In addition, an increase in cell death at more advanced life stages 
contributes to further reduce neuron number.  
 
Neurogenesis alterations 
The fact that brain and cerebellar volume reduction and cortical hypocellularity 
are already present in children and fetuses with DS (Sylvester 1983; Schmidt-
Sidor, Wisniewski et al. 1990; Golden and Hyman 1994; Winter, Ostrovsky et al. 
2000; Pinter, Eliez et al. 2001) strongly suggests that defective neuronogenesis 
during critical phases of brain development may be a major determinant of 
microencephaly. 
Due to the obvious difficulties in obtained fetal material, very little information is 
available concerning neurogenesis in the fetal DS brain. Our group recently 
obtained evidence that in fetuses with DS cell proliferation is severely impaired in 
the DG (most likely due to alteration of the cell cycle), in the germinal matrix of 
the inferior horn of the lateral ventricle and in the germinal zones of the 
hippocampus proper and parahippocampal gyrus (Contestabile, Fila et al. 2007; 
Guidi, Bonasoni et al. 2008). Quantification of the number of mature neurons and 
astrocytes in the hippocampus and parahippocampal gyrus showed that in all these 
regions fetuses with DS had proportionally fewer neurons and a larger number of 
astrocytes compared with normal fetuses (Guidi, Bonasoni et al. 2008). In 
trisomic fetuses, our group found a defective neurogenesis in the EGL of the 
cerebellum, and in a region of the fifth lobe that is the remnant of the cerebellar 
VZ (Guidi, Ciani et al.). This evidence clearly shows proliferation impairment in 
numerous regions of the fetal DS brain. Importantly, these defects are shared by 
trisomic mice (see below) which validates the use of mouse models for DS and 
renders evidence obtained in mouse model transferable to the human condition. 
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Dendritic hypotrophy 
Dendritic pathology is a typical feature of the DS brain and DS neurons exhibit 
patent alterations in dendriitic pattern and spine density and shape. In the visual 
cortex of fetuses with DS neuronal morphology is similar to that of control fetuses 
(Takashima, Becker et al. 1981). Likewise, the dendrites of layer IIIc pyramidal 
neurons of the prefrontal cortex in 2.5-month-old infants with DS is similar to that 
of normal cases (Vuksic, Petanjek et al. 2002). Dendritic abnormalities, however, 
begin to appear at later ages. A study in a 3 month-old infant with DS shows that 
interneurons in the motor cortex have a lower dendritic area (Prinz, Prinz et al. 
1997). The pyramidal neurons of the visual cortex of newborns older than 4 
months and older infants with DS have shorter basilar dendrites (Takashima, 
Becker et al. 1981). Dendritic hypotrophy is also present in pyramidal neurons of 
the parietal cortex of children with DS (Schulz and Scholz 1992). The dendritic 
hypotrophy seen in childhood continues into adulthood, with a marked decrease in 
dendritic branching and dendritic length in elderly adults with DS (Takashima, 
Ieshima et al. 1989). In the visual cortex of children with DS, the total dendritic 
length is above normal in the infantile period (6 months old or less) but drops 
steadily to below normal in juvenile subjects (older than 2 years) (Becker, 
Armstrong et al. 1986). This reduction contrasts with expanding dendritic 
arborization in normal children. These data indicate that in individuals with DS 
the dendritic tree atrophies in early childhood without a recovery at subsequent 
life stages.  
While in the visual cortex of fetuses with DS spine counts (basilar dendrites) are 
similar to those of control fetuses, newborns and older infants with DS have a 
decreased number of spines and spines exhibit an altered morphology 
(Takashima, Becker et al. 1981). In normal subjects, spine density on the basal 
dendrites of cortical pyramidal neurons increases from neonate to 15 years of age 
and gradually decrease after 20 years. In contrast, spine density poorly increases 
in children and rapidly decreases in adults with DS (Suetsugu and Mehraein 1980; 
Takashima, Ieshima et al. 1989; Takashima, Iida et al. 1994). A reduced spine 
density has been found in the apical dendrites of pyramidal neurons of the 
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hippocampus and cingulate cortex and in both the apical and basilar dendritic 
arbors of CA1 and CA2-3 pyramidal neurons in patients with DS when compared 
to age-matched control (Suetsugu and Mehraein 1980; Takashima, Ieshima et al. 
1989; Takashima, Iida et al. 1994). An additional decrease in spine density occurs 
in DS patients with associated AD, when compared to age-matched controls, and 
DS with no AD (Takashima, Ieshima et al. 1989; Ferrer and Gullotta 1990). The 
dendritic spines of the DS brain exhibit, in addition to reduced density, also 
aberrant morphology. Studies of infants with DS demonstrated that spines were 
small, had short stalks and were intermingled with unusually long spines (Marin-
Padilla 1976; Purpura 1979). Considering that drebrin expression is reduced in DS 
individuals (Shim and Lubec 2002), a reduced excitatory-inhibitory ratio is 
expected in DS individuals, which may lead to neuron hypoexcitation. 
 
Biochemical alterations 
Biochemical alterations also occur in fetal DS brain, which could serve as 
substrates for the morphological changes (Engidawork and Lubec 2003). In 
addition to the cholinergic system, that undergoes alterations at advanced life 
stages, the glutamatergic, serotonergic, noradrenergic and GABAergic systems 
are profoundly altered in DS individuals and in trisomic mice (Wisniewski and 
Bobinski 1991; Risser, Lubec et al. 1997). Alterations involve neurotransmitter 
levels as well as defects of receptor expression/function. 
Although young children with DS appear to be born with a normal 
septohippocampal cholinergic system (Kish, Karlinsky et al. 1989), an aging-
dependent neurodegeneration of the basal forebrain cholinergic neurons (BFCNs) 
was observed (Yates, Simpson et al. 1983; Casanova, Walker et al. 1985). 
Because BFCNs provide the major cholinergic input to the hippocampus and 
neocortex, the degeneration of these neurons may have functional consequences at 
level of cholinergic receptors. These dysfunctions could produce additional 
learning and memory deficits in older individuals with DS (Yates, Simpson et al. 
1983) and could be an outgrowth of the Alzheimer disease in these patients. In 
addition, an early onset of an Alzheimer disease-like neurohistopathology is 
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systematically observed by the fourth decade (Dalton and Crapper-McLachlan 
1986). 
 
2.1.8 The Human Chromosome 21, genotype–phenotype 
correlations 
Chromosome 21 (HSA21) is the smallest human autosome that represents around 
1±1.5% of the human genome. Different hypotheses have been presented to 
account for the relationship between trisomy 21 and the occurrence of DS 
phenotypes. The effects of trisomy on brain phenotypes have been explained by 
two hypotheses: 1) the “gene-dosage effect” hypothesis claims that DS 
phenotypes are determined by increased dosage of a subset of dosage-sensitive 
genes, and of their encoded proteins, especially during development (Delabar, 
Theophile et al. 1993; Korenberg, Chen et al. 1994; Ait Yahya-Graison, Aubert et 
al. 2007; Lyle, Bena et al. 2009), and 2) the “amplified developmental instability” 
hypothesis holds that Hsa21 trisomy determines a general alteration in 
developmental homeostasis (Roizen and Patterson 2003; Antonarakis, Lyle et al. 
2004). The gene-dosage hypothesis proposes that the 50% increase in expression 
at the RNA level of trisomic genes is the initiating cause of the DS phenotype. 
Recent experiments using microarrays and quantitative RT-PCR of human DS 
and mouse model samples indicate that the majority of trisomic genes in the 
majority of tissues indeed show increased expression, although not always by 
precisely 50% (Mao, Zielke et al. 2003; Amano, Sago et al. 2004; Kahlem, Sultan 
et al. 2004; Lyle, Gehrig et al. 2004; Dauphinot, Lyle et al. 2005). The triplicated 
genes could modulate directly or indirectly the expression of target genes on both 
the Hsa21 and the other chromosomes, determining a secondary gene dosage 
effect. Thus, the gene expression alterations in the brain, resulting from the 
different genetic mechanisms in response to the gene over-dosage in DS, may 
induce primary phenotypes at cellular level consisting in alterations in cellular 
processes, such as proliferation, differentiation, synaptogenesis, dendritogenesis 
and apoptosis in neuronal and glial cells. Even though several genes have been 
identified that are deregulated in DS brains, the challenge in DS research is to 
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establish a correlation between the functions of triplicated genes and features of 
the cognitive and behavioral phenotypes seen in DS.  
 
2.2. MOUSE MODELS FOR DS 
Although studies in DS cases with partial trisomy have helped to suggest 
chromosomal regions and HSA21 genes that may contribute to various 
phenotypes, the ability to resolve the basis of neurological and other phenotypes is 
limited. The use of animal models, particularly the mouse, is an invaluable tool 
for understanding underlying genetic and molecular mechanisms of DS. The 
advantages are: (1) the ability to study a large number of animals in a short time; 
(2) the availability of mice engineered to contain a specific gene(s); (3) the ability 
to control for genetic background; (4) the low cost of screening; (5) the ability to 
carry out studies on both developing and mature subjects; (6) the ability to design 
and execute a variety of therapeutic interventions; and (7) the lack of postmortem 
delay. The number and variety of these models is growing (Fig 5). At the genomic 
level, the long arm of the human chromosome 21 (Hsa21) is approximately 33.7 
Mb in length and contains about 430 protein-coding genes of which 293 have a 
homolog in the mouse genome. These genes are found in syntenic regions 
localized on three different mouse chromosomes. From the centromeric to the 
telomeric end of the Hsa21, the first and largest region is found on Mmu16 (about 
37 Mb in length with 224 orthologous genes), followed by a smaller region on 
Mmu17 (1.1 Mb in length with 22 orthologous genes) and finally a region on 
Mmu10 (2.3 Mb in length with 47 orthologous genes). In these three syntenic 
regions, relative order and orientation of the genes are preserved between the two 
species. With the introduction of new genetic engineering methods, it will be 
possible to produce additional models in which triplication of smaller genetic 
segment is readily accomplished. 
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2.2.1 Mice Trisomic for the entire MMU16 
Ts16 Mice trisomic for the entire 16th chromosome (Ts16) were generated by 
spontaneous Robertsonian translocation. Unfortunately, these mice die in utero, 
thus limiting research during the postnatal period. Death probably occurs as the 
result of cardiovascular abnormalities and insufficient placenta function 
(Miyabara, Gropp et al. 1982). A number of studies focused on nervous system 
abnormalities in Ts16 fetuses showed similarities with DS. These changes ranged 
from delayed development to degenerative processes. There is delayed cortical 
development in Ts16 mice. The cross-sectional area of cortical layers appears 
normal at E13. However, at E16, the cortical thickness is significantly (12–48%) 
smaller when compared with that of disomic mice (Haydar, Blue et al. 1996). 
Interestingly, 2 days later (E18) no such a difference could be detected. In 
addition to delayed development, a degenerative process has been found in these 
mice. Sweeney et collaborators (Sweeney, Hohmann et al. 1989) quantified the 
number of acetylcholinesterase (AChE)-positive neurons in the basal forebrain of 
Ts16 mice and found a significant (40%) loss when compared with controls. In a 
recent study, Dorsey et al.(Dorsey, Bambrick et al. 2002) studied brain derived 
neurotrophic factor (BDNF) signaling in Ts16 cultured hippocampal neurons and 
found evidence supporting failed tyrosine receptor kinase (TrkB)-mediated BDNF 
signaling in these cells. Accordingly, TrkB phosphorylation was significantly 
(33%) reduced in response to BDNF in Ts16 mouse hippocampal neurons. 
Moreover, trisomic cells were characterized with increased levels of a truncated, 
kinase-deficient isoform (T1) of the TrkB (TrkB T1). Interestingly, disruption of a 
gene encoding this protein restored the survival of cultured cortical and 
hippocampal Ts16 neurons. Although Ts16 mice have been extremely helpful in 
directing our attention to the probability that mouse model scan be used to study 
DS, this model suffers from severe practical and theoretical limitations. Because 
they do not survive birth, we are largely prevented from studying age-dependent 
degenerative effects. Furthermore, in addition to carrying orthologues of HSA21, 
MMU16 harbors orthologues of genes on humanchromosomes 3, 16, and 22. 
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2.2.2 Segmental MMU16 trisomic mice 
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Figure 5: Mouse models of Down syndrome. Schematic representation of Hsa21 
and corresponding regions of Mmu10 (hatched region), Mmu16 (gray region) and 
Mmu17 (black regions). Different mouse models that carry different triplication of 
different sets of genes orthologous to those of Hsa21 are indicated.  
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Ts65Dn Davisson et collaborators (Davisson, Schmidt et al. 1990), using 
irradiation, induced reciprocal translocation of T(16C3-4;17A2) and generated a 
mouse segmentally trisomic for MMU16 entitled Ts65Dn (Fig 6). The triplicated 
region of MMU16 in Ts65Dn extends from Znf295 to Mrp139 and contains at 
least 132 genes (Fig. 6). Ts65Dn mice recapitulate a variety of DS structural and 
functional changes. Similar to DS, basal forebrain cholinergic neurons (BFCNs) 
undergo age dependent degeneration in these mice (Cooper, Messer et al. 1999; 
Hunter, Bimonte et al. 2003; Salehi, Delcroix et al. 2004; Seo and Isacson 2005). 
The degeneration was linked to a marked decrease in the retrograde transport of 
nerve growth factor (NGF), a keytrophic factor for these neurons. By delivering 
NGF via intracerebro ventricular injection of NGF, and thus bypassing the 
retrograde transport, degenerative changes were rapidly reversed, even in very old 
Ts65Dn mice (Cooper, Messer et al. 1999). BFCNs project extensively to the 
hippocampus and cortex (Salehi, Delcroix et al. 2003). In a series of careful 
studies, marked synaptic structural abnormities were detected in these and other 
brain regions in Ts65Dn mice (Belichenko, Masliah et al. 2004; Kleschevnikov, 
Belichenko et al. 2004). Kurt and collaborators (Kurt, Kafa et al. 2004) studied 
neuronal density in the CA1 area of the hippocampus in old Ts65Dn mice and 
found a significant reduction in cell density. No such a difference was found at 3 
months of age (Lorenzi and Reeves 2006). Furthermore, a significant reduction in 
the area and number of dendritic branches, spine density and in the layer III 
pyramidal cells in Ts65Dn mice has been reported (Kurt, Kafa et al. 2004). 
Alterations in spine size and density in Ts65Dn hippocampus were associated 
with failure to induce long-term potentiation (LTP) in the dentate gyrus and CA1 
area (Kleschevnikov, Belichenko et al. 2004; Costa and Grybko 2005). In 
behavioral analyses, Ts65Dn mice showed significant spatial and non spatial 
learning disabilities, as shown by the hidden platform and probe tests in the 
Morris water maze (MWM) (Sago, Carlson et al. 2000; Hyde, Crnic et al. 2001; 
Hyde, Frisone et al. 2001). Ts65Dn mice are the most used model for DS.  
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Ts2Cje Since male Ts65Dn are infertile, only females can be used for breeding. 
Furthermore, the occurrence in progenyis ~20–25%. The Epstein Laboratory 
discovered a new mouse model called Ts2Cje that was generated by spontaneous 
Robertsonian fusion in which the triplicated segment in Ts65Dn was fused to 
mouse chromosome12 (Villar, Belichenko et al. 2005). Although the litter size in 
Ts2Cje mice is similar to those of Ts65Dn, the frequency of progeny bearing Rb 
(12.1716) has been reported to be higher than Ts65Dn mice (~43%). Furthermore, 
both male and female Ts2Cje mice are fertile. In terms of central nervous system 
changes, there was a significant decrease in spine density on the dendrites of 
dentate granule cells together with enlarged dendritic spines (~38%) in Ts2Cje 
mice (Villar, Belichenko et al. 2005), very similar to the changes described in 
Ts65Dn mice (Belichenko, Masliah et al. 2004). The functional consequences of 
these changes in Ts2Cje mice are yet to be explored. 
 
Ts1Cje Crossing balanced T(12:16)1Cje to wild type mice produced trisomic 
mice for a fragment of MMU16 extending from Sod1 to Znf295, but not including 
 
Figure 6: Ts65Dn mouse model. A) Ts65Dn and control mouse. B) 
Ts65Dn mouse model shows segmental trisomy for a distal region of 
chromosome 16, a region that shows perfectly conserved linkage with 
human chromosome 21. C) Fluorescent in situ hybridization (FISH) in 
Ts65Dn mouse. 
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a functional copy of Sod1 (Sago, Carlson et al. 1998; Sago, Carlson et al. 2000). 
Ts1Cje mice harbor three copies of ~78% of genes triplicated in Ts65Dn mice 
(Olson, Roper et al. 2004). There are important similarities between Ts1Cje and 
Ts65Dn mice in regards to CNS structural changes as enlargement of dendritic 
spines, decreased density of spines, and selective reorganization of inhibitory 
afferents (Belichenko, Kleschevnikov et al. 2007). Unlike hippocampal changes, 
no evidence of shrinkage and loss of markers in BFCNs in old Ts1Cje mice have 
been shown (Salehi, Delcroix et al. 2006). In accordance with this finding, NGF 
transport in the septo-hippocampal pathway in Ts1Cje mice was significantly 
increased relative to that in the Ts65Dn mouse suggesting that one or more genes 
in the segment that distinguishes Ts65Dn and Ts1Cje mice contribute 
significantly for the dramatic reduction of NGF transport. 
Failure in synaptic plasticity as measured by LTP have been reported in the both 
CA1 area (less severe than Ts65Dn) (Siarey, Villar et al. 2005) and dentate gyrus 
(Belichenko, Kleschevnikov et al. 2007) of hippocampus in Ts1Cje mice. The T 
maze spontaneous alternation task is abehavioral paradigm known to reveal 
dysfunction of the hippocampal system (Gerlai 2001; Lalonde 2002). Comparing 
Ts65Dn and Ts1Cje mice, both mice differed significantly from that of the 
corresponding 2N mice (Belichenko, Kleschevnikov et al. 2007). In the context of 
Morrison water maze, while Ts1Cje mice do show abnormalities in spatial 
learning and memory, they are less severe than in Ts65Dnmice (Sago, Carlson et 
al. 1998; Sago, Carlson et al. 2000). 
 
Ms1Ts65Dn Ms1Ts65Dn mice are produced by crossing Ts65Dn mice with 
T(12:16)1Cje mice (Sago, Carlson et al. 1998; Sago, Carlson et al. 2000). They 
are segmentally trisomic for the genetic segment from Mrp139 to Sod1, but not 
including a functional copy of Sod1. Unlike Ts65Dn, which are found to be 
hyperactive, and Ts1Cje, which are hypoactive, Ms1Ts65Dn mice were found to 
be normally active. Sago et al. (Sago, Carlson et al. 2000) compared the 
performance of these mice with Ts65Dn and Ts1Cje mice in the Morrison water 
maze and found that Ms1Ts65Dn mice did significantly better. In the reverse 
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probe test (preference score), and unlike Ts65Dn mice, neither Ts1Cje nor 
MS1Ts65Dn mice showed a significant difference with 2N mice (Sago, Carlson et 
al. 2000). Ms1Ts65Dn mice have not yet been studied extensively for changes in 
the structure and function of circuits involved in cognition. 
 
Ts1Rhr Comparing DS patients with segmental trisomy 21 has suggested that 
triplication of a 5.4 Mb region ofHSA21 called DS critical chromosomal region 
(DSCR) is associated with various DS phenotypes (Korenberg, Chen et al. 1994). 
In 2004, Olson et al. (Olson, Roper et al. 2004) reported generation of a new 
mouse called Ts1Rhr. These mice have a 3.9-Mb duplication of DSCR. This 
region contains mouse orthologues of the 33 genes in the human DSCR (i.e., 
around 32% of triplicated genes in Ts65Dn mice), with boundaries at Cbr1 
andMx2 genes. Surprisingly, it was found that, unlike Ts65Dn, Ts1Rhr mice do 
not show a smaller skull or mandible. This indicates that the genes causing facial 
features of DS are not located inthe DSCR. Relatively a very few studies have 
focused on brain abnormalities in Ts1Rhr mice. Recently, Aldridge et al. 
(Aldridge, Reeves et al. 2007) studied brain volume and found a significant 
(~20%) reduction in the entire brain as well as the cerebellum. 
 
Ts1Rhr/Ts65Dn Using a similar strategy as for Ts1Rhr, Olson et al. (Olson, 
Richtsmeier et al. 2004) deleted DSCR to produce a mouse trisomic for most of 
the genes trisomic in Ts65Dn (70%) but with only the two copies of DSCR 
(Ts1Rhr/Ts65Dn). No results of nervous system function have yet been reported. 
Macroscopic analysis of Ts1Rhr/Ts65Dn mice showed ~18% reduction in the 
brain volume and abnormalities in around 80% of linear brain distances 
(Aldridge, Reeves et al. 2007) indicating a significant changes in the brain shape. 
Studies on craniofacial features showed that with the exception of brachycephaly, 
Ts65Dn and Ts1Rhr/Ts65Dn mice have similar craniofacial measurements. This 
suggests that DSCR is not sufficient to produce the phenotypes present in 
Ts65Dn. These studies are important because they chart the direction that future 
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studies will take in examining the contribution of gene segments and individual 
genes. 
 
Tc1Yu Since Ts65Dn mice have three copies of a segment of MMU16 as well as 
a small portion of MMU17, Li and collegues (Li, Yu et al. 2007) recently reported 
generation of another DS mouse model with triplication of a larger segment of 
MMU16 without any contribution from MMU17. Using Cre/loxP-mediated 
chromosomal engineering, the Yu laboratory generated stem cells with 
duplication of MMU16 between D930038D03Rik and Zfp295genes (~22.9 Mb). 
Only 38% of Tc1Yu mice survive birth and no gross abnormality was detected 
through at least the age of 10 months. Around 37% of Tc1Yu mice suffer from 
cardiovascular abnormalities as early as E18.5. Furthermore, gastrointestinal 
abnormalities e.g., annular pancreas have also been reported. No studies on CNS 
related phenotypes have yet been reported. 
 
Dp(10)1Yey/+;Dp(16)1Yey/+;Dp(17)1Yey/+ Recently a new mouse DS model 
that carries duplications spanning the entire Hsa21 syntenic regions on all 
Mmu10, Mmu16 and Mmu17 mouse chromosomes has been created 
(Dp(10)1Yey/+;Dp(16)1Yey/+;Dp(17)1Yey/+). This mouse mutant exhibits DS-
related neurological defects, including impaired learning/memory and decreased 
hippocampal LTP (Yu, Li et al. 2010), very similarly to the Ts65Dn mouse. These 
results suggest that the critical genes associated with the DS brain phenotypes 
may reside within the Mrpl39–Zfp295 genomic segment of the Mmu16 and 
support the use of the Ts65Dn mouse as the best genetic murine DS model. 
 
2.2.3 Mice trisomic for HSA21 
Tc1 An additional category of mouse model for trisomy 21 resulted from the 
insertion of all or part of Hsa21. The Tc1 trans-species mouse strain, carrying an 
almost entire Hsa21, was developed using irradiation microcell-mediated 
chromosome transfer (O'Doherty, Ruf et al. 2005). This model exhibits several 
key phenotypes of DS (O'Doherty, Ruf et al. 2005; Morice, Andreae et al. 2008; 
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Galante, Jani et al. 2009). The most obvious CNS morphological changes found in 
Tc1 mice was a reduction in the density of cerebellar granule neurons in old Tc1 
mice. Abnormalities in hippocampal dependent learning and memory as well as 
decreased LTP have been detected in physiological studies in the dentate gyrus of 
the hippocampus. Using a novel-object recognition task, Tc1 mice spent 
significantly shorter times exploring novel objects. Interestingly, no difference 
was found between Tc1 mice and their control littermates in the spontaneous 
alternation T-maze; another test of hippocampal-related cognition (O'Doherty, 
Ruf et al. 2005). One short coming of this model is a high degree of mosaicism 
within tissues. For instance, only approximatelyone-third of brain cells was found 
tocarry HSA21. Examining brain phenotypes will require careful attention to 
which cells maintain HSA21 and which do not. Furthermore, effective 
transmission of HSA21 is possible only by out crossing to achieve a mixed strain 
background (O'Doherty, Ruf et al. 2005). Thesefindings are evidence for the 
propensity of mouse cells to eliminate HSA21. Finally, the consequences of 
expression of a large number of human proteins in mouse micro-environment 
must be taken into account in interpreting the phenotypes detected. 
 
2.2.4 Transgenic mice with triplication of individual genes 
Several transgenic mice that express from one or a few genes to entire segments 
of HSA21 (YAC transgenic mice) have been produced. As expected, none of 
these recapitulates the entire phenotype of DS, but many have features that are 
reminiscent of aspects of the phenotype. Transgenic mice containing the human 
Cu-Zn Superoxide dismutase 1 (SOD1) gene were the first mice produced to 
contain a gene encoded on HSA21 (Epstein, Avraham et al. 1987). These mice 
have some features that are similar to those seen in people with DS (Avraham, 
Sugarman et al. 1991; Gahtan, Auerbach et al. 1998). Many investigators have 
produced transgenic mice that express normal and mutant forms of beta-amyloid 
peptide (APP), and have demonstrated learning and memory deficits in these 
mice, including performance decline with age. In a recent experiment, compound 
transgenic mice that express human SOD1 and APP were created (Harris-Cerruti, 
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Kamsler et al. 2004). Working memory and long-term memory are severely 
impaired in these double transgenic mice; they have defects in APP processing, 
lipofuscin accumulation and mitochondrial anomalies. These findings are 
intriguing in light of the increasing evidence for a link between mitochondrial 
dysfunction, oxidative stress, APP processing and DS (Busciglio, Pelsman et al. 
2002). Other genes that cause phenotypes that are relevant to DS when 
overexpressed in transgenic mice include PFKL (Peled-Kamar 1998), the 
Drosophila minibrain homolog gene (DYRK1A) (Dierssen, Ortiz-Abalia et al. 
2006), the neurotrophic factor S100 β (Krapfenbauer, Engidawork et al. 2003), the 
transcription factor ETS2 (Wolvetang, Wilson et al. 2003) and the transcription 
factor single-minded (SIM2) (Chrast, Scott et al. 2000). Sim2 is overexpressed in 
Ts1Cje mouse fetuses (Vialard, Toyama et al. 2000) and in trisomic tissues (Lyle, 
Gehrig et al. 2004).Variations of SIM2 expression level were found in the 
cerebellum, cortical layers, and hippocampus (Rachidi, Lopes et al. 2005), key 
human brain regions involved in learning and memory that also are altered in DS 
patients (Raz, Torres et al. 1995; Pinter, Eliez et al. 2001; Rachidi, Lopes et al. 
2005). The transgenic mice overexpressing Sim2 (Tg Sim2) display reduced 
sensitivity to pain and mild impairment of learning (Ema, Ikegami et al. 1999; 
Chrast, Scott et al. 2000). These behavioral anomalies found in the Sim2 
transgenic mice remembered some phenotypes observed in trisomic mouse 
models for DS, Ts65Dn and Ts1Cje (Coussons-Read and Crnic 1996; Sago, 
Carlson et al. 1998; Martinez-Cue, Baamonde et al. 1999) and in DS patients 
(Hennequin, Allison et al. 2005). 
Two transgenic mouse models overexpressing DYRK1A have been generated. 
The first one, carried a human YAC 152F7, containing DYRK1A (Smith, Stevens 
et al. 1997); the second, carried the full-length DYRK1A cDNA (Altafaj, 
Dierssen et al. 2001). In the Morris water test, the transgenic lines carrying the 
YAC 152F7 showed lower performance in the probe test, in which the platform is 
removed. In the reverse learning paradigm, the transgenic mice showed the most 
severe deficits with no significant learning of the new platform position, 
indicating deficits in learning flexibility. Mouse line carrying a 152F7 YAC 
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fragment (152F7tel) containing only the DYRK1A gene, showed the same 
phenotype than the original YAC lines, indicating that the correct dosage of 
DYRK1A gene is crucial for brain function, learning and memory (Smith, Stevens 
et al. 1997). The two models show a significant impairment in spatial learning and 
memory, indicating hippocampal and prefrontal cortex function alteration. These 
transgenic mice showed increased brain weight and neuronal size (Branchi, 
Bichler et al. 2004) and dysfunction of reference memory (Smith, Stevens et al. 
1997; Altafaj, Dierssen et al. 2001). They also exhibit neurodevelopmental 
defects, delayed craniocaudal maturation and motor dysfunction (Altafaj, Dierssen 
et al. 2001). All these alterations are comparable with those found in murine 
models of DS with trisomy of chromosome 16, and suggest a causative role of 
DYRK1A in mental retardation and motor anomalies in DS patients. Moreover, 
DYRK1A-deficient mice have defects in central nervous system development, 
and DYRK1A appears sensitive to gene dosage as heterozygous mutant mice 
show limited changes in central nervous system development (Fotaki, Dierssen et 
al. 2002). The YAC 230E8 mouse lines showed altered density of neurons in 
cerebral cortex (Rachidi, Lopes et al. 2005). This abnormal density of neurons 
may explain the learning and memory deficits of these animals in the Morris 
water test (Smith, Stevens et al. 1997).The YAC 230E8 contains the DOPEY2 
gene, a new member of the Dopey family involved in morphogenesis that has 
been suggested as a candidate gene for the neurological alterations and mental 
retardation observed in these mice (Rachidi, Lopes et al. 2005). Ideally, transgenic 
mouse models of DS would contain a single extra copy of the relevant gene and 
regulatory elements that are similar enough to wild-type genes to assure typical 
spatio-temporal patterns of expression. These conditions are rarely achieved 
(Patterson and Costa 2005). Also, most transgenic mice contain human 
transgenes, and these might not be appropriately expressed in mice. Nonetheless, 
it is remarkable that these individual transgenes, and sometimes combinations of 
transgenes, have phenotypes that are reminiscent of DS. Construction of more 
transgenic mice seems well justified (Patterson and Costa 2005). 
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2.2.5 Segmental trisomic mice disomic for individual genes 
 Ts65Dn: App+/+/-. One critical question in understandingthe biology of DS is 
whether individual genes play a significant role in creating important phenotypes. 
To address this, Epstein et al. (Epstein, Berger et al. 1990) generated Ts65Dn 
mice with the normal two copies of specific genes (e.g., amyloidprecursor protein, 
App). This was achieved by breeding Ts65Dn female swith males in which one 
copy of the App gene was deleted. Ts65Dn: App+/+/- are viable and have no 
gross nervous system abnormalities with normal life span (Cataldo, Petanceska et 
al. 2003). Cataldo et al. (Cataldo, Petanceska et al. 2003) studied the endosomal 
system in Ts65Dn mice (with three copies of App) and found enlarged early 
endosomes in the basal forebrain as early as 2 months. Interestingly, these 
changes were not found in Ts65Dn mice withonly two copies of App. 
Significantly, they did not detect changes in endosomes in mice that are 
transgenic for mutant App. However, a recent report has documented an increase 
in early endosomes size and number (Laifenfeld, Patzek et al. 2007). Deleting one 
copy of App markedly improved NGF retrograde transport in Ts65Dn mice, 
reaching a level similar to that seen in Ts1Cje mice. Morphological analysis of 
BFCNs revealed that the increase in NGF retrograde transport was accompanied 
by a significant improvement in BFCN morphology in the medial septal nucleus 
(MSN). Indeed, this parameter did not distinguish the Ts65Dn: App+/+/- mice 
from their 2N controls (Salehi et al., 2006). 
 
2.3 NEUROGENESIS ALTERATIONS IN DS ANIMAL 
MODELS 
During the last few years various groups have tackled the issue of neurogenesis 
impairment in the DS brain by taking advantage of various mouse models.  
In Ts16 mice the number of precursors of the future somatosensory cortex just 
before neuronogenesis begins, is notably reduced. At each cell cycle during 
neuronogenesis, a smaller proportion of Ts16 progenitors exit the cell cycle and 
the cell cycle duration is longer in Ts16 than in euploid progenitors (Haydar, 
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Nowakowski et al. 2000). In the Ts65Dn mouse a reduced proliferation has been 
detected at all examined life stages. Reduced neural precursor proliferation is 
already present during embryonic development in the hippocampal region and 
VZ, with a reduction in the number of neocortical and hippocampal neurons 
(Chakrabarti, Galdzicki et al. 2007). The reduced neurogenesis appears to be due 
to elongation of the cell cycle. Interestingly, the neurogenesis defects of Ts65Dn 
mice lead to an imbalance between production of excitatory and inhibitory 
neurons In particular, Chakrabarty et al. found that the medial ganglionic 
eminence (MGE) (which gives origin to inhibitory neurons) of Ts65Dn mice at 
E14.5 undergoes divisions at a normal rate but gives a higher neuronal output due 
to a large progenitor population. The large output from the MGE explains the 
observation that in the neocortex and hippocampus of neonate and young Ts65Dn 
mice there are fewer excitatory but more inhibitory neurons (Chakrabarti, Best et 
al. 2010). The excessive production of inhibitory interneurons is due to over-
expression of the triplicated genes Olig1 and Olig2, as normalization of their 
expression rescues the Ts65Dn phenotype. In Ts65Dn mice, the postnatal SVZ of 
the lateral ventricle, which is the largest neurogenic area of the adult brain, 
exhibits a remarkably reduced proliferation rate that starts in the perinatal period 
and continues up to senescence (Bianchi, Ciani et al. 2010; Bianchi, Ciani et al. 
2010; Trazzi, Mitrugno et al. 2011). A severe neurogenesis reduction has been 
also documented in the embryonic neocortex and VZ and in the SVZ of adult 
Ts1Cje and Ts2Cje mice (Ishihara, Amano et al. 2010). In the adult Ts1Cje SVZ 
trisomy does not appear to affect the number of neural stem cells but results in 
reduced numbers of neural progenitors and neuroblasts (Hewitt, Ling et al. 2010). 
Analysis of differentiating Ts1Cje neural progenitors shows a severe reduction in 
number of produced neurons, whilst the number of astrocytes is increased 
(Hewitt, Ling et al. 2010). 
A severe neurogenesis impairment characterizes the DG of the Ts65Dn mouse at 
all examined life stages (Insausti, Megias et al. 1998; Lorenzi and Reeves 2006; 
Contestabile, Fila et al. 2007; Bianchi, Ciani et al. 2010). The study of the 
phenotype acquired by differentiating neural progenitor shows a reduction in the 
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number of new neurons with an increase in the number of astrocytes 
(Contestabile, Fila et al. 2007; Bianchi, Ciani et al. 2010). A severe neurogenesis 
reduction has been documented also in the DG of adult (3 months) Ts1Cje and 
Ts2Cje mice (Ishihara, Amano et al. 2010). 
Neurogenesis in the EGL of the cerebellum, A reduced proliferation of cerebellar 
granule cell precursors in the EGL of Ts65Dn mice has been documented at P0 
and P6 (Roper, Baxter et al. 2006). A reduced proliferation has been confirmed in 
P2 Ts65Dn mice, linked to elongation of the cell cycle (Contestabile, Fila et al. 
2008). Moreover, in Ts65Dn mice the percentage of newborn cells that acquire a 
neuronal phenotype is smaller vs. euploid mice, while the percentage of cells that 
acquire an astrocytic phenotyoe is larger (Contestabile, Fila et al. 2008).  
 
The widespread neurogenesis impairment observed in animal models and 
fetuses with DS during critical developmental stages strongly suggests that 
this defects may be a major determinant of the reduced brain size and, hence, 
of mental retardation. The proliferation impairment is worsened by reduction in 
neuronogenesis, (with a reduction in the production of excitatory neurons and an 
increase in the production of inhibitory neurons) and a relative increase in 
gliogenesis. Thus, both regulation of cell proliferation and differentiation are 
disrupted in the DS brain.  
 
2.4 MOLECULAR MECHANISMS UNDERLYING 
NEUROGENESIS IMPAIMENT IN DS 
A recent observation supports the possibility that Dyrk1a over-expression may be 
responsible for the generation of an inadequate number of neurons in cortical 
structures of the brain (Yabut, Domogauer et al.). DYRK1A is located within the 
DS critical region (Song, Sternberg et al. 1996), and is overexpressed in the DS 
brain (Guimera, Casas et al. 1999). Several studies using transgenicmice have 
demonstrated that Dyrk1a over-expression leads to cognitive impairment (Altafaj, 
Dierssen et al. 2001; Branchi, Bichler et al. 2004). Recently, it was 
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demonstratedthat Dyrk1a over-expression inhibits proliferation and 
inducespremature neuronal differentiation of neural progenitor cellsin the 
developing mouse cerebral cortex (Yabut, Domogauer et al.). Specifically, 
Dyrk1a over-expression probably inhibits cell cycle progression through nuclear 
export and degradation of cyclin D1 in neurogenic neuroepitheli. Another very 
recent report has shown that over-expression of Dyrk1a induces impaired G1/G0–
S phase transition in immortalized rat hippocampal progenitor cells (de la Monte, 
Ng et al.). The proposed mechanism is mediated by the phosphorylation of p53, 
which leads to the induction of p21CIP1. In terms of the possible role of Dyrk1a 
in neuronal differentiation, a recent report shows that the interaction and 
phosphorylation of the intracellular domain of Notch by Dyrk1a attenuates Notch 
signaling in transfected neural cell lines (Fernandez-Martinez, Vela et al. 2009). 
Since during neurogenesis, the cells in which Notch signaling is activated remain 
as progenitors, whereas those in which Notch activity diminishes differentiate into 
neurons (Louvi and Artavanis-Tsakonas 2006), it can be hypothesized that 
Dyrk1a may regulate the onset of neuronal differentiation by inhibiting Notch 
signaling. In addition, the capacity of Dyrk1a to interact with and⁄or modulate 
different signaling pathways (EGF, FGF, NGF, Shh, NFAT, etc.) (Tejedor, Zhu et 
al.), supports a key role played by Dyrk1a in coordinating neural 
proliferation/differentiation. 
Very recently, Chakrabarti et al. (Chakrabarti, Best et al. 2010) have shown that 
proper expression of two genes, Olig1 and Olig2, is essential during embryonic 
development for regulating the numbers of inhibitory neurons, a type of neuron 
that controls signaling in the brain. The authors found in the forebrain of Ts65Dn 
mice a complex set of neurogenesis defects that led to an imbalance between 
excitatory and inhibitory neurons and to increased inhibitory drive. Alterations in 
the number of neuronsas well as in the timing of differentiation is likely to lead to 
theformation of abnormal cortical circuits and, consequently, to thecognitive 
deficits observed in transgenic mice and DS patients. The combined restoration of 
Olig1 and Olig2 to disomy in Ts65Ds embryos rescued the abnormal 
neurogenesis responsible for the increased interneuron phenotype and restored 
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spontaneous inhibitory postsynaptic currents in CA1 pyramidal neurons 
(Chakrabarti, Best et al. 2010), supporting a re-establishment of normal neuronal 
function. This is in accordance with a recent study where the pharmacological 
block of the hyperactivity of inhibitory interneurons rescues some of the learning 
and electrophysiological deficits present in this mouse model (Fernandez and 
Garner 2007).  
It has been suggested that amyloid precursor protein (APP) over-expression may 
result in enhancement of the Notch signaling pathway (Fischer, van Dijk et al. 
2005), which is crucial for the acquisition of a glial phenotype (Morrison, Perez et 
al. 2000). Indeed, the expression of Notch1 is up-regulated in the cortex of DS 
and AD patients and in DS fibroblasts (Fischer, van Dijk et al. 2005), indicating 
that enhanced APP processing interferes with Notch signaling and probably 
affects phenotype acquisition during brain development.  
 
2.5 APP GENE AND NEUROGENESIS 
2.5.1 The human gene APP 
Human APP belongs to a highly conserved family of type 1 transmembrane 
glycoproteins which constitutes APP and the mammalian homologs APLP-1 and 
APLP-2, both homologs lacking the Aβ sequence (Goldgaber, Lerman et al. 1987; 
Wasco, Gurubhagavatula et al. 1993). The evolutionary conservation of APP gene 
family also extends to invertebrate species with its orthologs APPL in Drosophila 
and APL-1 in Caenorhabditis elegans respectively (Daigle and Li 1993). These 
proteins all share several conserved motifs within the large extracellular domain 
and a short cytoplasmic region which exhibits the highest sequence homology 
(Gralle and Ferreira 2007). The human APP gene contains 18 exons spanning 
more than 170 kbp. The region encoding the Aβ sequence comprises part of exons 
16 and 17 and is composed of 40 to 43 amino acid residues that extend from the 
ectodomain into the transmembrane domain of this protein (Fig. 7). The presence 
of multiple distinct domains located within the extracellular portion includes a 
signal peptide (SP), a heparin-binding/growth-factor-like domain 1 (HPBD1), a 
copper binding domain (CuBD), a zinc binding domain (ZnBD), a Kunitz-type 
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protease inhibitor domain (KPI), a second heparin-binding domain 2 (HPBD2), a 
random coil region (RC) and the Aβ sequence (Fig. 7). The remaining region 
consists of the cytoplasmic tail of APP, including its intracellular domain, AICD. 
Several isoforms of APP that arises from alternative splicing have been identified 
and the most common forms differ mainly by the absence (APP-695) or presence 
(alternatively spliced APP-751 and APP-770) of a KPI domain (Kitaguchi, 
Takahashi et al. 1988; Konig, Monning et al. 1992). 
 
 
2.5.2 Proteolytic processing of APP 
APP can undergo amyloidogenic or non-amyloidogenic processing via cleavage 
by different secretases (Ling, Morgan et al. 2003). The amyloidogenic processing 
of APP, cleaved initially by β-secretase, produces a long soluble secreted form of 
APP (sAPPβ) and a carboxy-terminal fragment (CTF99) containing the Aβ 
sequence and AICD (Fig. 8). In the brain, β-site APP cleaving enzyme (BACE1) 
has been found to be the major β-secretase (Vassar, Bennett et al. 1999). In the 
 
1
Figure 7: Schematic diagram of APP consisting of a large extracellular 
domain, a hydrophobic transmembrane domain and a short cytoplasmic 
carboxyl terminus. The protein is proteolytically processed by different 
secretases via amyloidgenic and non-amyloidgenic proceeding 
pathways which either releases the Aβ peptide (cleaved by β- and γ-
Modifies picture from Zhou, Z. et al, 2011  
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alternative non-amyloidogenic pathway, APP could also be proteolytically 
processed by a presenilin-containing α-secretase complex, which cleaves at a site 
within Aβ sequence and consequently abrogates Aβ formation (Ling, Morgan et 
al. 2003). The non-amyloidogenic cleavage releases a carboxy-terminal fragment 
(CTF83) and another soluble fragment (sAPPα) which, in contrast to Aβ, may be 
neuroprotective (Furukawa, Sopher et al. 1996; Mattson 1997; Han, Dou et al. 
2005). Both CTF99 and CTF83 fragments are then sequentially cleaved within the 
transmembrane domain by γ -secretase to generate AICD and Aβ or p3 
respectively (Chow, Mattson et al. 2010). Elevated β -secretase levels were found 
to induce the increase of CTF99 and Aβ generation as well as the decrease of 
CTF83 and AICD generation in vitro. On the contrary, elevated levels of α -
secretase was found to induce an increase in AICD levels (Kume, Maruyama et al. 
2004). Therefore α -secretase and β –secretase cleavage of APP might influence 
subsequent AICD release differently. The details of amyloidogenic and non-
amyloidogenic processing of APP are illustrated in Fig. 8. 
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2.5.3 Role of APP in neurogenesis 
Recent accumulative evidence demonstrated that APP is important for neuron 
generation, neuron differentiation and neural migration. In nematode 
Caenorhabditis elegans, loss of APL-1 by genetic inactivation resulted in 
postnatal lethality due to abnormalities in multiple developmental processes such 
as molting defects. This phenotype could be successfully rescued by expressing 
the extracellular domain of APL-1 in neurons (Hornsten, Lieberthal et al. 2007). 
Furthermore APP was found to be important in Drosophila melanogaster, as 
deletion of the APPL gene leads to behavioral defects in phototaxis that could be 
Figure 8: APP processing procedure and cleavage products. The non-
amyloidogenic APP processing pathway (right) involves proteolytic 
cleavages by α- and γ-secretases resulting in the generation of sAPPα 
and carboxyl terminal fragments including P3, CTF83 and AICD. The 
alternative amyloidogenic APP processing pathway (left) involves 
proteolytic cleavages by β- and γ-secretases resulting in the generation 
of sAPPβ and carboxyl terminal fragments including Aβ, CTF99 and 
and AICD. Aβ peptides could oligomerize and fibrillize leading to AD 
pathology. sAPPα could function to promote neurogenesis and survival, 
while AICD could have effects to inhibit neurogenesis possibly via 
forming complex with Fe65 and leading to transcriptional regulation.  
 
Modifies picture from Zhou, Z. et al, 2011  
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partially rescued by human APP (Luo, Tully et al. 1992). Interestingly, highly 
elevated APPL levels were observed in regenerating neurons of a Drosophila 
brain injury model (Leyssen, Ayaz et al. 2005). In contrast, lack of this stress 
response in APPL mutant flies increased mortality (Vassar, Bennett et al. 1999). 
As an upregulation of APPL correlated with an increase in neurite arborization, a 
potential role in axonal outgrowth after traumatic brain damage was attributed to 
APP (Leyssen, Ayaz et al. 2005). Another study showed that APPL 
overexpression promoted synapse differentiation, while APPL mutants resulted in 
decreased synaptic bouton numbers at the neuromuscular junction in Drosophila 
(Torroja, Packard et al. 1999). APP is also ubiquitously expressed in mammalian 
cells and was found to have complicated physiological roles in cell adhesion, 
neuronal differentiation, neuronal migration, neurite outgrowth and synapse 
formation (Breen, Bruce et al. 1991; Young-Pearse, Bai et al. 2007). The 
immunoreactivity of APP was found to increase after brain injury of mice, which 
correlated well with traumatic brain injury (Johnson, Stewart et al. 2010). APP 
knockout mice showed reductions in weight, deficits in balance and strength, 
impairments in behavior and long-term potentiation (Zheng, Jiang et al. 1995; 
Dawson, Seabrook et al. 1999). The evidence from other APP knockout in vivo 
animal model systems demonstrated potential roles of APP in neuron generation, 
differentiation as well as neural migration (Bergmans, Shariati et al. 2010). Taken 
together, these findings corroborate a potential crucial role for APP as part 
of a complex mechanism involved in a wide variety of neuronal functions, 
including normal neural development or response to traumatic brain 
injuries. Cumulative evidence suggests that the soluble sAPPα is neuroprotective 
and is associated with growth factor-like functions, while the interaction of AICD 
with a myriad of proteins links it with diverse processes such as axonal transport 
and transcriptional regulation. 
 
2.5.4 Role of sAPPα in the positive regulation of neurogenesis 
The physiological functions of sAPPα have been implicated in the enhancement 
of synaptogenesis, neurite outgrowth, cell survival and cell adhesion (Mattson 
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1997; Gakhar-Koppole, Hundeshagen et al. 2008). In separate reports, sAPPα has 
been observed to exert proliferative effects on NPC isolated from the embryonic 
brains (Ohsawa, Takamura et al. 1999; Caille, Allinquant et al. 2004). In 2005, 
Caille et al. first acquired evidence suggesting the in vivo role of sAPPα in adult 
neurogenesis (Caille, Allinquant et al. 2004). The authors found that sAPPα binds 
prominently to cells of the subventricular zone (SVZ), one of the two adult central 
nervous system sites harboring NPC that are capable of regeneration in the adult 
brain (Caille, Allinquant et al. 2004). Their findings suggested that sAPPα were 
likely to participate in the EGF-induced proliferation of type A cells, although 
sAPPα alone fails to induce proliferation of these cells (Caille, Allinquant et al. 
2004). The authors also observed that infusion of sAPPα into the lateral ventricle 
of mice led to an increase in number of progenitor cells (Caille, Allinquant et al. 
2004). Conversely, blocking sAPPα secretion by α-secretase inhibitor or 
downregulating APP synthesis by antisense oligonucleotide against APP 
decreases the proliferation of EGF responsive cells, which leads to a reduction of 
the pool of progenitors (Caille, Allinquant et al. 2004). Their results also showed 
that sAPPα activity may be delivered in an autocrine/paracrine manner (Caille, 
Allinquant et al. 2004). The crystal structure analysis at 1.8 Å resolution of APP 
further demonstrated that its cysteine-rich N-terminal heparin-binding domain is 
similar to other cysteine-rich growth factors, which is conceived to be responsible 
for its function to stimulate neurite outgrowth (Rossjohn, Cappai et al. 1999). 
These growth-promoting properties of sAPPs and its structural similarities with 
cysteine-rich growth factors suggest that sAPPs may function as a growth factor 
in vivo (Rossjohn, Cappai et al. 1999). Early in vitro studies have also 
demonstrated that sAPPα protects cultured neurons against hypoglycemia damage 
and glutamate neurotoxicity, through the activation of potassium channels which 
in turn mediates the ability of sAPPα to inhibit calcium influx and thus modulates 
neuronal excitability (Furukawa, Sopher et al. 1996), (Mattson, Cheng et al. 
1993). Taken together, these results suggest that sAPPα might function as specific 
growth factors or as a mediator for adult NPC proliferation. However, to date, no 
sAPPα receptors have been identified yet and the signaling pathways triggered 
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have not been thoroughly investigated. To this extent, it is of interest to note that 
two in vitro studies have reported a stimulation of MAP kinase activity by sAPPα 
and it would thus be of importance to dissect this signaling pathway triggered by 
sAPPα in detail (Yogev-Falach, Amit et al. 2002; Youdim, Amit et al. 2003). 
Intriguingly, sAPPα levels were shown to decrease in the cerebrospinal fluid 
(CSF) of AD individuals, while infusion of sAPPα into the brain increased 
synaptic density and improved memory retention (Meziane, Dodart et al. 1998). 
Therefore, these findings raised the possibility that sAPPα may contribute to 
neurogenesis in adult brain and sAPPα might be used for AD patients clinically, 
while decrease of sAPPα levels in brain may be an indispensable precondition for 
AD pathogenesis. 
 
2.5.5 Role of AICD in the negative modulation of neurogenesis 
AICD was termed by analogy to NICD (Notch intracellular domain) formed by 
the regulated intramembrane proteolysis (RIP) of another type I transmembrane 
glycoprotein Notch. Both AICD and NICD were produced via cleavage of APP or 
Notch by the same γ-secretase complex respectively. Extracellular binding of 
Notch to its ligand is one of the mechanisms responsible for this regulation of 
cleavage, stimulating release of NICD in cells (Selkoe and Kopan 2003).The 
NICD translocates into the nucleus and leads to a series of downstream signaling 
cascades. 
Although multiple proteins have been reported to interact with AICD including 
Fe65 that may be necessary for AICD-dependent signaling, no functional ligands 
for APP have been characterized so far (Ma, Futagawa et al. 2008). Recently Ma 
et al. discovered that transient axonal glycoprotein 1 (TAG1), a neural cell 
adhesion molecule of the F3 family, acts as an extracellular binding partner for 
APP through the immunoglobulin (Ig) and fibronectin repeat (FNIII) domains of 
TAG1 (Ma, Futagawa et al. 2008). The author found that TAG1 and APP co-
expressed in NPC in the neurogenic niche of the ventricular zone in developing 
mouse brains (Ma, Futagawa et al. 2008). It was also found that the extracellular 
interaction between APP and TAG1 was essential for initiating the release of 
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AICD which could be abrogated by the presence of specific γ-secretase inhibitors 
(Ma, Futagawa et al. 2008). It was further confirmed in knockout in vivo studies 
that the interaction between TAG1 and APP negatively modulates neurogenesis 
through release of AICD and triggers a Fe65-dependent molecular event (Ma, 
Futagawa et al. 2008). These findings provided valuable insights that APP could 
function as a transmembrane receptor protein which negatively mediates 
neurogenesis through recognition of its specific cell surface-associated ligands 
(Ma, Futagawa et al. 2008). 
However, the detailed mechanism by which AICD suppresses neurogenesis 
still remains to be elucidated. Several questions regarding TAG1-APP signaling 
pathway including its potential contributory roles in adult brain development and 
AD pathogenesis also remain unanswered. What physiological functions does this 
signaling pathway eventually mediate? As yet, few immediate downstream target 
genes have been identified for AICD and Fe65. Based on the resemblance of 
molecular structure and processing procedure between Notch and APP as well as 
known knowledge of the Notch cascade, it would be tempting to speculate that the 
AICD generated by γ-secretase cleavage may be capable of inducing an 
intracellular signaling pathway via modulationof gene expression after interaction 
with its adaptor protein Fe65. The interaction between AICD and Fe65 may 
promote the translocation of AICD directly to the nucleus or may initiate a Fe65-
mediated nuclear signal independently of AICD translocation. However, the 
hypothesis that AICD could function to modulate transcriptional activity in cells 
appears highly controversial so far. Although numerous studies have suggested 
that AICD can regulate expression of various endogenous genes including KAI1, 
GSK-3b, APP and neprilysin, other groups were unable to replicate these findings 
(Ryan and Pimplikar 2005; Hebert, Serneels et al. 2006). To this extend, it is 
interesting to note that several recent studieshave reported AICD-expressing 
transgenic mice recapitulate AD-like pathological features as activation of GSK-
3β, phosphorylationand aggregation of tau, memory deficits and aberrant neural 
activity and seizure susceptibility (Ryan and Pimplikar 2005; Vogt, Thomas et al. 
2011). The authors showed that overexpressed AICD impairs adult 
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neurogenesis intransgenic mice through induction of neuroinflammation, which 
could be prevented by treatment with anti-inflammatory drugs (Vogt, Thomas et 
al. 2011). However although inflammation may play a pivotal role in impaired 
neurogenesis in AICD transgene mice, abnormally expressed AICD may also 
confer its deleterious effects via stimulation of GSK-3β activity and alteration of 
the activity of Wnt signaling pathway, which has been shown to perturb 
neurogenesis in mice and in AD patients (Goodger, Rajendran et al. 2009). This 
hypothesisties in with previous studies suggesting that AICD is capable of 
regulating the expression of various endogenous genes including GSK-3β (Ryan 
and Pimplikar 2005). In contrast, other groups were unable to replicate these 
findings (Aydin, Filippov et al.; Hebert, Serneels et al. 2006). Therefore a 
conclusive understanding of the APP signaling pathway related to regulation 
of neurogenesis by AICD would be necessary as it may offer unique 
opportunitiesfor pharmacological intervention of AD in the future. 
The influence of neurogenesis by APP fragments was illustrated in Figure 9.  
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2.5.6 APP and DS  
Over-expression of several genes localized in chromosome 21 has been linked to 
neuronal death, including APP (Busciglio, Pelsman et al. 2002). Fibrillar amyloid 
beta-protein (Aβ) is a major component of amyloid plaques in the brains of 
individuals with AD and of adults with DS. Some effects of Aβ are linked to 
oxidative stress-dependent apoptosis. Tamagno et al. (Tamagno, Robino et al. 
Figure 9: Schematic diagram for influence of neurogenesis by 
sAPPa and AICD. The α secretases cleavage of APP could release 
sAPPa into extracellular space, which could function on cells 
possibly via binding with its specific receptors. The sAPPa could 
function to promote NPC proliferation and positively regulate 
neurogenesis. On the contrary, g-secretases cleavage of APP could 
release AICD into cytoplasm, which could complex with Fe65 and 
enter nucleus. The AICD and Fe65 complex might function to 
transcriptionally regulate gene expressions related to neurogenesis, 
including miRNAs genes. Finally AICD will function to inhibit 
neuronal differentiation via so far unknown mechanisms, hereby 
negatively regulate neurogenesis. 
 
Modifies picture from Zhou, Z. et al, 2011  
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2003) proposed the existence of a sequence of events in Aβ-induced apoptosis, 
involving simultaneous generation of a lipid-peroxidation products such as 4-
hydroxynonenal, H2O2, and oxidative stress-dependent activation of c-Jun 
aminoterminal kinase (JNK) and the mitogen-activated protein kinase p38 
(MAPK) (Fig. 10). On its way to deposition in the brain, Aβ induces oxidative 
changes causing nerve cell insults. Increasing evidence indicate that Aβ 
overproduction, besides inducing extensive amyloidosis, possibly triggers early 
cognitive impairment in dementia in DS by altering synaptic activity (Conti and 
Cattaneo 2005; Gasparini and Dityatev 2008). In fact, Aβ aggregated oligomeric 
species profoundly affect synaptic plasticity of excitatory synapses by blocking 
LTP in vitro and in vivo (Lambert, Barlow et al. 1998; Walsh, Klyubin et al. 
2002; Wang, Pasternak et al. 2002; Townsend, Shankar et al. 2006; Shankar, Li et 
al. 2008) and enhancing LTD (Li, Hong et al. 2009) via down-regulation of 
NMDARs and inhibition of glutamate reuptake (Li, Hong et al. 2009). Fibrillar 
oligomeric Aβ species have been detected within thioflavine S-negative diffuse 
Aβ plaques in AD and DS brain (Sarsoza, Saing et al. 2009). Importantly, it has 
been shown that amyloid dimers isolated from AD brain impair synaptic plasticity 
and reduce dendritic spine density in rodent hippocampus (Shankar, Li et al. 
2008). However, further investigation is needed to ascertain whether similar Aβ 
soluble aggregates contribute to alteration of synaptic activity in DS. βAPP 
upregulation is also causally linked to BFCN (basal forebrain cholinergic 
neurons) degeneration in trisomic mice. It has been demonstrated that βAPP 
overexpressionin Ts65Dn mice impairs the retrograde transport of nerve growth 
factor (NGF) from the hippocampus to the basal forebrain, causing degeneration 
of BFCN (Salehi, Delcroix et al. 2006) through axonal mechanisms resulting in 
enlargement of early endosomes and βAPP overload (Cataldo, Petanceska et al. 
2003; Chang and Gold 2008) (Salehi, Delcroix et al. 2006). Indeed, the 
degenerative phenotype is reversed by NGF infusion (Cooper, Salehi et al. 2001). 
Ts1Cje mice, which are trisomic for a smaller MMU16 segment missing βAPP, 
lack any evident BFCN degeneration (Cataldo, Petanceska et al. 2003; Salehi, 
Delcroix et al. 2003, Salehi, 2006 #2403). BFCN degeneration and endosomes 
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abnormalities are also prevented by restoring βAPP gene dosage to two copies in 
Ts65Dn mice (Cataldo, Petanceska et al. 2003; Salehi, Delcroix et al. 2006), 
suggesting that βAPP is one of the dosage sensitive gene the orized by the 
‘‘dosage imbalance hypothesis’’ and is the main responsiblefor AD pathology in 
DS. Aβ overproduction may also contribute to the development of tau inclusions. 
In fact, it has been shown that the formation of cerebral tau aggregates is 
accelerated by injecting Aβ in the brainof tau transgenic mice or by crossing mice 
bearing human mutated tau with mutant βAPP overexpressing mice (Gotz, Chen 
et al. 2001; Lewis, Dickson et al. 2001). Finally, βAPP-mediated pathological 
mechanisms may also occur during development. It has been suggested that βAPP 
overexpression may result in increased Notch signalling pathway, which is crucial 
for neuronal and glial differentiation (Fischer, van Dijk et al. 2005). Indeed, the 
expression of Notch1, Dll1 (delta-like 1) and Hes1 (hairy and enhanced of split 1) 
is up-regulated in the cortex of DS and AD patients and in DS fibroblasts 
(Fischer, van Dijk et al. 2005), indicating that enhanced βAPP processing 
interferes with Notch signalling. Importantly, emerging evidence indicates that 
βAPP and its secreted ectodomain βAPPs play a crucial role in regulating the 
proliferation of neural progenitors during development (Chen and Tang 
2006) and adulthood (Conti and Cattaneo 2005), strogly suggest a 
potentiallink between βAPP overexpression and altered brain developmentin 
DS. 
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2.6 HEDGEHOG SIGNALING 
The Hedgehog (Hh) signaling, through its family of secreted proteins, governs a 
wide variety of processes during embryonic development and adult tissue 
homeostasis. Hedgehog (hh) was initially discovered by Christiane Nusslein- 
Volhard and Eric Wieschaus nearly 30 years ago as a ‘‘segmentpolarity’’ gene 
that controls Drosophila embryonic cuticle pattern (Nusslein-Volhard and 
Wieschaus 1980). Since the molecular cloning of hh and the discovery of its 
vertebrate counterparts in the early 1990s, enormous progress has been made in 
revealing the role of Hh signaling in development and disease as well as the 
molecular underpinning of the Hh signaling cascade. It is well known that Hh 
signaling is not only important in fruit flies to pattern their embryonic cuticles and 
adult appendages, but vital for diverse aspects of animal development and 
essential in humans to regulate cell fate and number in their brains and spinal 
Figure 10: The pathogenesis of AD involving Aβ induced toxicity via 
increased ROS and dysregulation of intracellular calcium as well as 
altered neurogenesis due to imbalance between positive regulation of 
neurogenesis by sAPPα and negative regulation of neurogensis by 
AICD.  
 
Modifies picture from Zhou, Z. et al, 2011  
 52 
cords, to pattern their limbs and internal organs, and even to control their body 
heights (Ingham and McMahon 2001; Weedon and Frayling 2008). Recent studies 
have also implicated Hh signaling as essential for stem cell maintenance (Beachy, 
Karhadkar et al. 2004). Not surprisingly, malfunction of Hh signaling contributes 
to numerous human disorders including birth defects, such as Gorlin syndrome 
and Greig cephalopolysyndactyly syndrome, and cancer including basal cell 
carcinoma and medulloblastoma (McMahon, Ingham et al. 2003; Nieuwenhuis 
and Hui 2005).  
 
2.6.1 Sonic Hedhehog (Shh) signaling 
Sonic Hedhehog (Shh), along with Indian hedgehog (Ihh), and Desert hedgehog 
(Dhh) is a member of the Hedgehog family of secreted glycoproteins, which 
affects the development of many organs and cell groups (Riddle, Johnson et al. 
1993; Porter, Young et al. 1996). Synthesized as a large precursor protein, Shh 
undergoes autoproteolysis and lipid modifications of its biologically active 
aminoterminal domain (ShhN). Shh mediates its action via a receptor complex 
associating two transmembrane proteins: Patched (Ptch) displaying a transporter-
like structure and Smoothened (Smo), a putative member of the G protein-coupled 
receptor superfamily. The repression exerted by Ptch on Smo is relieved when 
Shh binds Ptch, which leads to a complex signaling cascade involving the 
transcription factors of the Gli family and finally, to the activation of target genes 
including Ptch and Gli themselves (Huangfu and Anderson 2006; Ruiz i Altaba, 
Mas et al. 2007). At the cell membrane, the glycoprotein Hedgehog-interacting 
protein (Hhip) binds Shh with high affinity and acts as a negative regulator of Hh 
signaling in the embryo (Fig. 11). Like Ptch, Hhip is a target gene positively 
regulated by the Hh pathway. Both participate in an inhibitory mechanism of Hh 
signal by sequestering, modifying, or degrading the ligand at the cell surface 
(Jeong and McMahon 2005). Ptch induces rapid endocytosis and subsequent 
lysosomal degradation of Shh (Incardona, Lee et al. 2000), whereas Hhip appears 
to only physically sequester Shh at the cell surface (Jeong and McMahon 2005).  
After relief of the inhibition exerted by Ptch on Smo, the canonical Hh pathway 
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leads to the transcription of target genes. This activity is mediated through the 
inhibition of Gli transcription factor processing into their transcriptional repressor 
forms and the concomitant accumulation of transcriptional activators. Su(Fu), a 
negative regulator of Shh signaling, interacts with the three vertebrate Gli proteins 
(Gli1, Gli2, Gli3) to retain them in the cytosol (Merchant, Evangelista et al. 2005; 
Jia, Kolterud et al. 2009) and also to control Gli function at nuclear level (Cheng 
and Bishop 2002; Barnfield, Zhang et al. 2005). These proteins contain five zinc-
finger DNA-binding domains and differ by their N-terminal domains (Varjosalo, 
Li et al. 2006; Riobo and Manning 2007; Ruiz i Altaba, Mas et al. 2007). Gli1 is 
considered as a mean to amplify the Hh response rather than a direct effector of 
the Hh transduction machinery. However, Gli1 is a target gene of the pathway and 
is classically used as a convenient readout for the pathway activation. Gli2 would 
function mainly as a transcriptional activator, but could also display a repressor 
activity in specific contexts. Conversely, Gli3 mainly functions as a 
transcriptional repressor even though recent studies have also shown that Gli3 can 
act as an activator in vivo (Varjosalo, Li et al. 2006; Riobo and Manning 2007; 
Ruiz i Altaba, Mas et al. 2007). 
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Figure 11: Proposed model for Sonic Hedgehog signaling pathway. Shh 
uses the primary cilia to induce its signal. (A) In the absence of Shh 
ligand, the receptor Ptc is located in the cilium and represses Smo found 
mostly outside the cilium, by a yet unknown mechanism. The repressor 
forms of the transcription factors Gli (Gli-R) enter the nucleus and inhibit 
Shh target gene transcription. The negative regulator of the pathway 
Su(Fu) interacts with the activator (Gli-A) and repressor (Gli-R) forms of 
Gli maintaining them out of the nucleus and also controlling Gli function 
at nuclear level. Hip is a negative regulator able to directly bind Shh and 
is found as both membrane-associated and soluble forms. Gas1, Cdo and 
Boc are other membrane proteins able to bind Shh. (B) In the presence of 
Shh, Ptc is internalized, Smo inhibition is relieved allowing its 
translocation and accumulation to the cilium, which likely involves its 
interaction with β-arrestin (β-Arr). In the cilium, Smo may inhibit the 
formation of Gli-R, and activate Gli-A to promote the transcription of Hh 
target genes, such as Ptc and Gli1. 
Modified figure from Traiffort et al, 2010  
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2.6.2 Non-canonical Shh signaling 
Several non-canonical mechanisms of Shh signaling have also been reported 
(Jenkins 2009). Hh responses, involving Hh components without any Gli-
mediated transcription, have been proposed for Shh-induced cell migration 
(Bijlsma, Borensztajn et al. 2007), axonal guidance (Yam, Langlois et al. 2009), 
or modification of the electrophysiological properties of mature neurons (Bezard, 
Baufreton et al. 2003; Pascual, Traiffort et al. 2005). In the absence of Shh, Ptch 
may directly interact with Cyclin B1 (Barnes, Kong et al. 2001) or caspases 
(Thibert, Teillet et al. 2003), which inhibit cell proliferation or promote apoptosis, 
respectively. 
Along the same lines, the repressor form Gli3 generated in the absence of Shh 
signaling is also able to inhibit the canonical Wnt/β-catenin signaling (Ulloa, 
Itasaki et al. 2007). Lastly, Shh effects occuring in adhesion or migration of 
neuroepithelial (Jarov, Williams et al. 2003) or neural crest cells (Testaz, Jarov et 
al. 2001) are independent of the Ptch–Smo–Gli cascade, while the repulsive 
activity of Shh on postcommissural axons during the neural tube development is 
mediated by Hhip (Bourikas, Pekarik et al. 2005). 
 
2.6.3 Shh signaling in the developing Central Nervous System 
Of the three vertebrate Hh homologs, only Shh is found in the mammalian CNS. 
It is expressed both during embryogenesis and, as is becoming more well 
appreciated, also in adults, where its function may be related to one that is among 
the most commonly conserved across species and tissues: maintaining reservoirs 
of stem cells that are located in specific niches (Traiffort, Angot et al.; Ahn and 
Joyner 2005; Palma, Lim et al. 2005; Balordi and Fishell 2007). Shh begins to 
exert an influence over CNS development at the very earliest stages of 
embryogenesis when neural tissue is first allocated during gastrulation. At that 
time, expression is seen in the embryonic node, the undifferentiated group of cells 
that are responsible for producing the signals that induce neural ectoderm and then 
for ventralizing this tissue. At presumptive spinal cord levels, Shh expression is 
maintained in the mesodermal notochord underlying the ventral neural plate and 
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then, shortly thereafter, in the floor plate (FP), a small group of cells located at the 
ventral neural midline that disappear later in development. In the forebrain, 
midline mesodermal cells expressing Shh form the prechordal plate, which does 
not coalesce into a rod-shaped structure like the notochord. Here, too Shh 
expression is initially induced secondarily in the midline, but is soon 
downregulated as the hypothalamus and pituitary begin to arise, after which time, 
it is only expressed in two lateral domains in the approximate boundary between 
the future hypothalamic/thalamic boundary. After brain vesicle formation, Shh 
expression is also upregulated in the zona limitans intrathalamica (ZLI), a 
morphological dividing line between emerging thalamic nuclei in the caudal 
diencephalon that extends dorsally from the FP in the midbrain, and later still in 
distinct foci in the preoptic area, presumptive amygdala, and the medial 
ganglionic eminence (MGE), the anlage to the basal ganglia (Sousa and Fishell 
2010). Another region of the CNS where Shh expression has been characterized is 
in the developing cerebellum. Here, Shh is seen in postmitotic Purkinje cells, and 
from this source signals to granule cell precursors to support their extensive 
expansion (Wechsler-Reya and Scott 1999). This relationship has provided a 
unique opportunity to study the regulation of cell proliferation by Shh, a pursuit 
that has important clinical implications for understanding childhood brain tumors 
arising in the cerebellum (Hatten and Roussel; Vaillant and Monard 2009). Shh 
serves as an important early signal from all of these regions but its specific 
requirement varies. Early loss of Shh is associated with the most severe 
consequences, a failure to induce ventral midline neural tissue, resulting in 
holoprosencephaly and cyclopia, a condition where only a single forebrain vesicle 
and eye form (Chiang, Litingtung et al. 1996). Shh in the thalamic midline and 
ZLI is required to generate specific thalamic neuronal subtype (Jeong, Dolson et 
al. 2011). Loss of downstream Shh transduction components also results in the 
misspecification of ventral forebrain neuronal structures and subtypes (Carney, 
Mangin et al.; Cocas, Miyoshi et al. 2009; Xu, Guo et al. 2010). 
 
 
 57 
2.6.4 Shh signaling and Neural Stem Cells 
The Shh pathway has been extensively analyzed in neural stem and progenitor 
cells (Wechsler-Reya and Scott 1999; Dahmane, Sanchez et al. 2001; Lai, Kaspar 
et al. 2003; Machold, Hayashi et al. 2003; Ahn and Joyner 2005; Palma, Lim et al. 
2005; Balordi and Fishell 2007). Besides its multifaceted roles in the 
specification, proliferation, and differentiation of neural precursors during 
embryogenesis, Shh signaling is required for the maintenance of Shh-responsive, 
Gli1-positive quiescent neural stem cells in the adult brain (Ahn and Joyner 2005; 
Palma, Lim et al. 2005; Balordi and Fishell 2007). During cerebellar 
development, Shh secreted by the Purkinje cells promotes rapid proliferation of 
granule cell precursors in the external granular layer (Fig. 12) (Wechsler-Reya 
and Scott 1999), and Ptch mutations are commonly found in both familial and 
sporadic medulloblastomas. Studies of Ptch heterozygous Gorlin syndrome 
patients, as well as analogous mutant mice, have strongly suggested that Shh 
pathway activation is critical for the transformation of granule cell precursors 
(Goodrich, Milenkovic et al. 1997). However, it seems likely that the ability of the 
pathway to act in this fashion is nonetheless dependent on cell-type-specific 
determinants. For example, although the Shh pathway is activated in lowand high-
grade human gliomas, and Shh signaling positively regulates the self-renewal of 
glioma cancer stem cells (Clement, Sanchez et al. 2007; Ehtesham, Sarangi et al. 
2007), Gorlin syndrome patients do not develop gliomas. Consistent with this, 
two recent studies have demonstrated that Shh pathway activation in mouse neural 
stem cells or restricted neural progenitors induces only medulloblastoma, not 
glioma (Schuller, Heine et al. 2008). The cell-autonomous determinants that 
control Gli action in the nucleus only represent a small fraction of the range of 
mechanisms that control the Hh response. For example, in many developmental 
contexts, there is considerable regulation at the level of production, dissemination, 
and presentation of Hh ligands. 
 
 58 
 
 
2.6.5 Shh signaling and Neural Stem Cells in the SVZ and in the 
Hippocampus 
The fact that neurogenesis and gliogenesis continue in the adult mammalian brain 
(Alvarez-Buylla, Garcia-Verdugo et al. 2001) might explain why Shh is expressed 
in some sites of the mature brain. The intriguing role for hedgehog signaling in 
regulating the proliferation of adult neural progenitors has been widely studied in 
the mammalian forebrain. It is an excellent system for the analysis of adult neural 
stem cells because it has two localized areas of postnatal neurogenesis, the dentate 
gyrus of the hippocampus and the subventricular zone (SVZ) of the lateral 
ventricles. Whereas the hippocampal progenitors locally populate the 
hippocampus, the SVZ progenitors migrate along the rostral migratory stream to 
populate the olfactory bulb. Work in mice has shown that this SVZ niche consists 
Figure 12: In cerebellar development, Shh secreted by Purkinje cells controls the 
proliferation of granule neuron progenitors in the external germinal cell layer 
(EGL). 
 
Modified figure from Jin Jiang and Chi-chung Hui 2008 
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of quiescent (slow-cycling) progenitors, transit-amplifying cells and migrating 
neuroblasts. Using AraC anti-mitotic treatment to ablate rapidly dividing cells in 
the precursor and neuroblast lineages, it was shown that astrocyte-like cells could 
divide to replenish these two populations, indicating that a slowly dividing glial 
population serves as the SVZ stem cell (Doetsch, Caille et al. 1999). 
In vivo evidence highlighting the importance of hedgehog signaling in these two 
postnatal proliferative niches came from conditional genetic loss-of-function 
studies, viral gain-of-function studies and genetic fate mapping. Conditional 
removal of Smo in the brain at mid-gestation circumvents the early embryonic 
patterning defects seen in the Shh nulls and allows postnatal examination of the 
effects of Shh signaling in the dentate gyrus subgranular zone (SGZ) and SVZ 
proliferative regions (Machold, Hayashi et al. 2003). Both regions showed a 
marked reduction in the number of proliferating progenitors at 2–3 weeks after 
birth in these mutants, and the SVZ also showed increased cell death. As a result 
of these perturbations of the postnatal proliferative niches, the granule cell 
populations of both the hippocampus and the olfactory bulb were severely 
depleted. A similar decrease in proliferation was observed in the SVZ of juvenile 
mice that were administered a one week course of the Shh signaling inhibitor 
cyclopamine, and in the hippocampus of mice that had this inhibitor injected 
directly into the same region (Lai, Kaspar et al. 2003; Palma, Lim et al. 2005)In a 
series of experiments with interesting clinical implications, artificial stimulation 
of the hedgehog signaling pathway in the rodent forebrain led to increases in 
neural progenitor proliferation in both the SVZ and the dentate gyrus of the 
hippocampus. Activation of hedgehog signaling was achieved either through 
adenoviral delivery of the N-terminal active fragment of Shh (Lai, Kaspar et al. 
2003), or through the use of a small-molecule hedgehog agonist that upregulates 
signaling in hedgehog responsive tissues through interactions with Smo 
(Machold, Hayashi et al. 2003). This suggests that enhancing hedgehog signaling 
might be effective as a means of promoting neural repair. Although it seems clear 
that hedgehog signaling has an essential role in maintaining adult neural 
progenitor proliferation, the downstream mechanistic details are still largely 
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unknown. Genetic inducible fate mapping (GIFM) studies in mice (Joyner and 
Zervas 2006) have begun to illuminate the developmental history and cell-type 
specificity of Shh signaling in these proliferative niches (Ahn and Joyner 2005). 
Using Gli1 as a marker of hedgehog responding cells, it was definitively shown 
that quiescent and transit-amplifying stem cells in the adult SVZ and SGZ 
normally receive GLI activator signaling. Furthermore, the quiescent cells 
expressing GLI1 continue to give rise to neurons that populate the olfactory bulb 
and hippocampus for over a year and are multipotent. In addition, it seems that the 
SVZ and SGZ niches are formed sequentially towards the end of embryonic 
forebrain development. With regard to the cellular mediators of this process, 
analysis has shown that periventricular astrocytes, the characterized SVZ stem 
cell population, express not only Gli1 but also other components of the hedgehog 
signaling cascade (Palma, Lim et al. 2005). In vitro analysis of dissociated 
cortices of Gli2 and Gli3 mutants indicates that these genes could in part mediate 
the role of hedgehog in adult progenitor proliferation (Palma and Ruiz i Altaba 
2004). In addition to these issues, it will be interesting to better understand the 
source of the hedgehog signals that act in the two proliferative niches, as well as 
the instructive events in receiving cells that are directed by these signals. Finally, 
given the dichotomy between the proliferative response to Shh and its role in 
maintaining the adult stem cell niche, it will be interesting to determine whether 
this differential response reflects different mechanisms of Shh action or different 
functional effects in discrete lineages within the stem cell niche. 
 
2.2.6 Shh and DS 
Patients with Down Syndrom are characterized by a reduction of the granular cell 
layer volume in the cerebellum accompanied by hypotonia and fine motor control 
impairment (Latash and Corcos 1991). Similarly, Ts65Dn mouse model of DS has 
a reduction of the number of cerebellar granule cell precursors (CGPs), resulting 
from an insufficient mitotic rate. From exploring the mitotic deficit in Ts65Dn 
mice, Roper et collaborators (Roper, Baxter et al. 2006) found that trisomic GCP 
were less sensitive to the dually lipidated protein Shh. By injecting an analogue of 
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Shh into Ts65Dn pups at P0, the mitotic and GCP proficiency could be restored to 
that of euploid controls. Yet, the cause of this insensitivity which leads to a 
reduction in mitosis and to a reduction in CGPs density remains 
undetermined. Few clues can be found in transcriptome studies as to which 
aspect(s) of the Shh signalling pathway is affected. In the cerebellum, it is only in 
the postnatal external granule cell layer that genes involved in the Shh signalling 
pathway become expressed-genes such as Patched, Smoothened, Gli1 and Gli2 
(Sotelo 2004). Therefore, it is likely that only at this time can a deficit in the 
pathway manifest and be observed in DS.  
Roper et al, 2009 (Roper, VanHorn et al. 2009), found an attenuate response of 
NC (Neural crest) precursors to Shh in Ts65Dn mouse model of DS. NC 
contribute to the majority of the bone, cartilage, connective tissue and peripheral 
nervous tissue in the head (Santagati and Rijli 2003). The correct formation of the 
craniofacial skeleton is necessary for the proper development of the brain, sensory 
organs, and the normal functioning of the digestive and respiratory tracts 
(Santagati and Rijli 2003; Le Douarin, Brito et al. 2007). Because NC is a 
common precursor of many structures affected in DS, it has been hypothesized 
that Shh response deficits may represent cellular and molecular “common 
denominators” of pathogenesis contributing to multiple aspects of the 
trisomic phenotype in DS.  
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3. MATERIALS AND METHODS 
 
3.1 Ts65Dn MICE COLONY AND TREATMENT 
Female Ts65Dn mice carrying a partial trisomy of chromosome 16 (Reeves, 
Irving et al. 1995, Davisson, 1993 #211) were obtained from Jackson 
Laboratories (Bar Harbour, ME, USA) and maintained on the original genetic 
background by mating them to C57BL/6JEi x C3SnHeSnJ (B6EiC3) F1 males. 
Animals were karyotyped by real-time PCR (qPCR) as previously described (Liu, 
Schmidt et al. 2003). The animals had access to water and food ad libitum and 
lived in a room with a 12:12 h dark/light cycle. Experiments were performed in 
accordance with the Italian and European Community law for the use of 
experimental animals and were approved by Bologna University Bioethical 
Committee. In this study, all efforts were made to minimize animal suffering and 
to keep to a minimum the number of animals used.  
The day of birth was designed as postnatal day (P) zero.On P2, three euploid and 
three Ts65Dn mice received a subcutaneous injection (150 µg/g body weight) of 
BrdU (5-bromo-2-deoxyuridine; Sigma), a marker of proliferating cells in 0.9% 
NaCl solution and were killed after 2 h to examine cell proliferation. 
 
3.2 HUMAN FETUSES 
Human fetal brains (17-21 weeks of gestation) were obtained after prior informed 
consent from the parents and according to procedures approved by the Ethical 
Committee of the St. Orsola-Malpighi Hospital, Bologna, Italy. Regulations of the 
Italian Ministry of Health and the policy of Declaration of Helsinki were 
followed. All fetuses derived from legal abortions and were collected with an 
average post-mortem delay of approximately 2 hours. The brains of control 
fetuses (n = 3) and fetuses with DS (n = 3) used in the current study are the same 
used in previous studies (Contestabile, Fila et al. 2007; Guidi, Bonasoni et al. 
2008). Trisomy was caryotypically proved from the results of genetic 
amniocentesis procedures. Autopsies were performed at the Institute of Pathology 
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of the St. Orsola-Malpighi Hospital. The gestational age of each fetus was 
estimated by menstrual history and crown-rump length. Fetuses used in this study 
are summarized in the table below: 
 
CASE AGE (weeks) SEX CRL (cm) BW (gr) 
Control fetuses     
C164 19 F 14 285 
C27 20 F 17 230 
C178 21 M n.a. n.a. 
Down syndrome fetuses     
C166 19 F 14 240 
C133 20 M 16 300 
C46 21 M 22 355 
 
Table 1: List of the cases used in the present study. AGE refers to gestional 
age in weeks, CRL: crown-rump length; BW: body weight; n.a.: not 
available. 
 
3.3 HISTOLOGICAL PROCEDURES 
P2 mice were decapitated, brains removed, cut along the midline and fixed by 
immersion in Glyo-Fix (Thermo Electron Corp., Waltham, MA, USA) for 48 h 
and then dehydrated through a series of ascending ethanol concentrations. Each 
hemisphere was embedded in paraffin.Forebrainswere coronally sectioned in 8 
µm thick sections that were attached to poly-lysine-coated slides. Fetal brains 
were fixed by subdural perfusion with Metacarnoy fixative (methyl alcohol: 
chloroform: acetic acid 6:1:1). After 24 h, the hippocampal region was coronally 
sectioned into two to three blocks, with a 2–3 mm thickness. The first block 
roughly corresponded to the rostral third of the hippocampal formation. The 
blocks were post-fixed in formalin (4% buffered formaldehyde) for at least 5 
days, embedded in paraffin, according to standard procedures, and sectioned in 5 
µm thick coronal sections. 
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3.4 CELL CULTURES AND TREATMENTS 
Cells were isolated from the SVZ and hippocampus of newborn (P1–P2) euploid 
and Ts65Dn mice (Fig. 13) and neurosphere cultures were obtained as previously 
reported (Weiss et al, 1996; Pacey et al., 2006). 
 
 
 
 
Figure 13: Sagittal section of adult mouse brain. The subventricular 
zone is bounded by a green rectangle and the hippocampus by a red 
one. Scheme of the dissection protocol. The blue broken lines 
represent the coronal cuts at which the brain of P2 mice was cut for 
removing the rostral and caudal forebrain. 
 
Briefly, Ts65Dn and Euploid mice were decapited with sterile surgery scissors in 
the cell culture hood. The skulls were cut with a scalpel blade over the entire 
length. Gently skulls were broken and the brains removed and transferred to the 
dissection solution (Table 2) 
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Tissue dissection solution 
2.0 M NaCl 15.5 ml 
1.0 M KCl 1.25 ml 
1.0 M MgCl2 0.80 ml 
155 mM NaHCO3 41.90 ml 
1.0 M Glucose 2.50 ml 
108 mM CaCl2 0.23 ml 
DDW (Double Distilled Water) 188.0 ml 
Filter and store at 4°C and bubble with 95% O2/ 5% CO2 for 10 min before use 
 
 
 
Any remaining meninges were stripped from the surface of the brain taking 
advantage of a dissecting microscope. Then, forebrains were coronally cut in 
order to isolate the subventricular zone and the hippocampus from both the 
emispheres (Fig. 13). Tissues were fine cut into small pieces using curved scalpel 
blades and forceps and centrifuged for 1 minute at 250g. After removing the 
supernatant, enzyme mix (Table 3) was added for 10 min. at 37°C.  
 
Enzyme mix 
Trypsin  2BAEE/ml 
Type 1-S Hyaluronidase  12.12 µM 
Kynurenic Acid  704.72 µM  
Enzyme mix components are dissolved in 30 ml of tissue dissection solution and filter with 0.22 
µm filter Activities for trypsin are expressed in international units (IU) with BAEE as substrate. 
Unit definition: One BAEE unit will produce a ΔA253 of 0.001 per min at pH 7.6 at 25° C using 
BAEE as substrate 
 
 
In order to neutralize the effect of the enzyme mix, after centrifugatin for 5 
minutes at 250xg, tissues were resuspended in a solution containing trypsin 
Table 2: Tissue dissection solution composition 
 
Table 3: Enzyme mix composition 
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inhibitor (1.0 mg/ml in Serum Free Medium) and mechanically triturated (20 
times) with a Pasteur pipette to produce a single cell suspension. Cells were 
cultured in suspension in Dulbecco’s modified Eagle’s medium (DMEM)/F12 
(1:1) containing B27 supplements (2%), basic fibroblast growth factor (FGF-2, 20 
ng/ml), epidermal growth factor (EGF, 20 ng/ml), heparin (5 µg/ml) and 
antibiotics (penicillin: 100 units/ml; streptomycin: 100 µg/ml) and counted by 
Trypan Blue dye exclusion (density of ~ 10-15 cells/µl). Primary neurospheres 
were dissociated at days 8–10 using Accutase (PAA, Pasching, Austria) to derive 
secondary neurospheres. The sub-culturing protocol consisted of neurosphere 
passaging every 7 days with whole culture media change (with freshly added 
FGF-2 and EGF). All experiments were done using neurospheres obtained after 
three to five passages from the initially prepared cultures. Most (98%) of the cells 
in neurospheres from the SVZ and hippocampus were positive for nestin, an 
established marker for neural and glial precursors. Cell cultures were kept in a 5% 
CO2 humidified atmosphere at 37°C. Treatments were performed for 3 days after 
cell plating adding fresh reagents every 24 h.  
The following drugs were used: 3 µg/ml and 6 µg/ml recombinant mouse Sonic 
Hedgehog Peptide (Shh; Sigma), 250 nM benzo[b]thiophene-2-carboxamide,3-
chloro-N-[4-(methylamino)cyclohexyl]-N-{[3(4 pyridinyl)phenyl] methyl}-(9CI) 
(SAG; Enzo life science), 10 µg/ml cyclopamine hydrate (Sigma), 5 µM 5-Aza-2′-
deoxycytidine (AZA; Sigma), 150 nM TSA (Sigma), 10 µM N-[N-(3,5- 
Difluorophenacetyl)-L-alanyl]-S-phenylglycine t-butyl ester (DAPT; Sigma) and 
1 nM Compound E (Enzo life science). 
 
3.5 NEUROSPHERES DIAMETER MEASURAMENTS 
Dissociated neurospheres were plated at a low density (2 x 104 cells/ml) and phase 
contrast images of cells were taken almost every day for 8 days using an Eclipse 
TE 2000-S inverted microscope (Nikon, Tokyo, Japan). Neurosphere diameters 
were measured with the NIS-Elements AR software (Nikon). 
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3.6 BRDU IMMUNOCYTOCHEMESTRY IN NEUROSPHERES 
For proliferation analysis, dissociated neurospheres were cultured for 3 days, 
treated with 10 µM BrdU for additional 16 h and harvested on microscope slides 
by cytospin centrifugation (215g, 5 min, Shandon, Thermo, Dreieich, Germany). 
Specimens, processed as previously described (Hendzel, Wei et al. 1997), were 
incubated with a mouse anti-5-bromo-2-deoxyuridine (BrdU) monoclonal 
antibody (1:100; Roche Applied Science) and a Cy3-conjugated anti-mouse 
secondary antibody (1:200; Sigma). Samples were counterstained with Hoechst-
33258. Digital images were captured using an Eclipse TE 2000-S microscope and 
the NIS-Elements AR software (Nikon). 
 
3.7 CELL CYCLE ANALYSIS IN NEUROSPHERES 
For determination of total cell cycle length (TC) and S-phase length (TS), the 
BrdU cumulative method was applied (Takahashi, Nowakowski et al. 1993, Li, 
2001). Neurospheres were treated with 10 µm BrdU for 1.5, 3.0, 4.5, 6.0, 24, 48 
and 72 h, and fixed and processed for BrdU immunocytochemistry. The labeling 
index (LI; number of BrdU-positive cells over total cell number) was evaluated in 
12 random fields for each sample. LI values obtained at each time point for 
control and trisomic neurospheres were then plotted as a function of time after 
BrdU administration as previously described (Contestabile, Fila et al. 2009; 
Contestabile, Fila et al. 2009). Using a linear regression analysis, a least-squares 
line was best-fitted to data points for each group. The y-intercept and the x-values 
for y = 1 extrapolated from the equation 
y= a*x + b 
were used to calculate the total length of the cell cycle (TC) and the length of the S 
phase (TS) as previously described (Fujita et al., 1967). The y-intercept (the b 
parameter of the equation above, i.e. the LI at x = 0) represents the length of the S 
phase over total cell cycle length: 
TS / TC = b 
and the time at which all cells are labeled (y = 1) represents the interval TC - TS: 
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TC - TS = (1-b)/a 
By solving the system of the two equations above, TC and TS can be calculated: 
TC = 1/a 
TS = b/a 
The number of cells in G2 or M phase of cell cycle over total cell number is 
proportional to the length of G2 (TG2) or M (TM) phase over total cycle length. 
Therefore, TG2 and TM were estimated from the G2I and MI obtained with pHH3 
immunohistochemistry and total length of cell cycle (TG2/TC= G2I; TM/TC= MI): 
TG2 = G2I * TC 
TM = MI * TC 
Finally, the length of the G1 phase was obtained by subtracting from the total 
length of the cell cycle the length of the other phases:  
TG1= TC - (TS+TG2+TM) 
 
3.8 IN VITRO DIFFERENTIATION ANALYSIS OF NPCs 
Neurospheres obtained after three passages in vitro were dissociated and plated on 
cover slips coated with 15 µg/ml poly-L-ornithyine (Sigma). Cells were grown for 
2 days and then transferred to a differentiating medium (EGF and FGF free plus 
1% foetal bovine serum) for 7 days. Every 3 days, half of the medium was 
replenished with fresh differentiating medium. Differentiated cells were fixed on 
slides by cytospin centrifugation and incubated with anti-glial fibrillary acidic 
protein (1:400; GFAP mouse monoclonal, Sigma) and anti-β-Tubulin III (1:100; 
rabbit polyclonal, Sigma), as primary antibodies, and with anti-mouse FITC-
conjugated (1:100; Sigma) and anti-rabbit Cy3-conjugated (1:100; Jackson 
Laboratories), as secondary antibodies. Samples were counterstained with 
Hoechst-33258. Cells were counted in five different fields of each cover slip. 
Number of positive cells for each antibody was referred to the total number of 
Hoechst-stained nuclei. 
 
3.9 PTCH1 QUANTIFICATION IN NEUROSPHERES 
For Ptch1 immunocytochemistry, we used an anti-Ptch1 rat monoclonal antibody 
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(1:50; R&D systems) and, as a secondary antibody, a Cy3-conjugated anti-rat 
antibody (1:200; Jackson Laboratories). Samples were counterstained with 
Hoechst 33258. To quantify Ptch1 expression, we used the NIS-Elements AR 
software (Nikon). For each neurosphere, the perimeter was traced and the mean 
intensity of the Ptch1 signal was derived by the ratio between the sum of the 
intensity of positive (bright) pixels and the area of single neurospheres. 
Approximately 3 neurospheres were analyzed from each slide (three euploid and 
trisomic mice and two slides for each condition). 
 
3.10 BRDU IMMUNOHISTOCHEMESTRY  
One out of 20 sections from the DG and SVZ of P2 animals was processed for 
BrdU immunohistochemistry. Sections were processed as previously described 
(Lowry, O.H et al; 1951) and incubated overnight at 4°C with a primary antibody 
anti-BrdU (1:100, Roche Applied Science). Detection was performed with a 
horseradish peroxidase (HRP)-conjugated anti-mouse secondary antibody (1:200; 
Jackson Immunoresearch) and DAB kit (Vector Laboratories). Sections were 
counterstained with hematoxylin. Bright field images where taken with a Leitz 
Diaplan microscope equipped with a motorized stage and a Coolsnap-Pro digital 
camera (Media Cybernetics, Silver Spring, MD). The sampled sections covered 
the whole rostrocaudal extent of the DG and a region of the SVZ that extended 
from the rostral pole of the lateral ventricle and stretches for ~900 µm in the 
caudal direction. The total number of BrdU positive cells was estimated by 
multiplying the number counted in the series of sampled sections by the inverse of 
the section sampling fraction (1/20). 
 
3.11 PTCH1 IMMUNOHISTOCHEMESTRY AND 
QUANTIFICATION IN VIVO 
One out of 12 sections, in P2 animals, and 2–3 sections of the series of 4–5 µm 
thick sections of human fetuses were stained using an anti-Ptch1 rabbit polyclonal 
antibody (1:50; ab39266 Abcam). Sections were retrieved with citrate buffer (pH 
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6.0) at 98°C for 40 min before incubation with the antibody and processed as 
previously described (Contestabile, Fila et al. 2007). Sections were incubated with 
Cy3-conjugated anti-rabbit (1:200; Jackson Laboratories) secondary antibody. 
Image processing and analysis were carried out using the NIS Elements AR 
software (Nikon). To quantify Ptch1 expression, we normalized the intensity of 
the signal from the SVZ of mice and hippocampal region of mice and fetuses to 
that of the corpus callosum and fimbria, respectively. 
 
3.12 WESTERN BLOTTING 
Collected neurospheres were lysated in ice-cold lysisbuffer. (1% Triton-X100, 
150 mM NaCl, 1 mM EDTA and 20 mM Tris pH 7.4) supplemented with 1mM 
PMSF and 1% proteases and phosphatases inhibitors cocktail (Sigma). Samples 
were then incubated in ice for 10 min and clarified by centrifugation at 10,000 x g 
for 10 min at 4 °C. (Contestabile, Fila et al. 2009). Protein concentration was 
estimated by the Lowry method (Lowry, Rosebrough et al. 1951). Proteins (30 
µg) were subjected to electrophoresis on an 8% sodium dodecyl sulphate (SDS)- 
polyacrylamide gel and transferred to a Hybond ECL nitrocellulose membrane 
(Amersham Life Science). and equal loading of protein in each lane was assessed 
by brief staining of the blot with 0.1% Ponceau S. Membranes were blocked for 1 
h in 5% milk, 0.1% Tween-20 in Tris-buffered saline (150 mM NaCl, 10 mM 
Tris-HCl, pH 8.0) and incubated overnight at 4 °C with the following primary 
antibodies: anti-Ptch1 rat monoclonal (1:50; R&D systems) and anti- β-actin 
(1:2000; Sigma) antibodies. Membranes were washed, incubated with HRP-
conjugated anti-rabbit (1:1000 dilution; Amersham Biosciences) and specific 
reactions revealed with the ECL Western blotting detection reagent (Amersham 
Biosciences). Densitometric analysis of digitized images was performed with 
Scion Image software (Scion Corporation, Frederick, MD, USA) and intensity for 
each band was normalized to the intensity of the corresponding β-actin band.  
For AICD detection, nuclear extracts from neurospheres were prepared. For the 
preparation of nuclear extracts cellswere allowed to swell and lysed in hypotonic 
buffer (Hepes, 10mM , NaCl, 50 mM , EDTA, 1 mM , Nonidet P-40, 0.1%, 
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dithiothreitol,1 mM , phenylmethylsulfonyl fluoride, 1 mM , pH 8) for10 min at 4 
°C. After centrifugation, nuclei were extracted withhypertonic salt buffer (Hepes, 
20 mM , NaCl, 420 mM , EDTA, 1mM , dithiothreitol, 1 mM , glycerol, 10%, 
phenylmethylsulfonylfluoride, 1 mM , pH 8). Cells extracts (40 µg) were 
subjected to electrophoresis on a 4–12% NuPAGE Bis-Tris gel (Invitrogen) and 
transferred to a nitrocellulose membrane. The membrane was processed for 
antigen-retrieval as previously described (Ryan and Pimplikar 2005). The blot 
was incubated with the anti-C-terminal APP rabbit primary antibody (1:8000; 
A8717 Sigma-Aldrich). 
 
3.13 QUANTITATIVE REAL-TIME PCR  
Total RNA was isolated from neurosphere cultures with Tri- Reagent (Sigma) 
according to the manufacturer’s instructions. cDNA synthesis was achieved with 
1.0 µg of total RNA using the iScriptTM cDNA Synthesis Kit according to the 
manufacturer’s instructions. We used the primers that gave efficiency close to 
100% (Table 4). Realtime PCR was performed using a SYBR Premix Ex Taq kit 
(Takara, Shiga, Japan) according to the manufacturer’s instructions in an iQ5 real-
time PCR detection system (Bio-Rad).  Fluorescence was determined at the last 
step of every cycle. Real-time PCR assay was done under the following universal 
conditions: 2 min at 50°C, 10 min at 95°C, 50 cycles of denaturation at 95°C for 
15 sec, and annealing/extension at 60°C for 1 min. Relative quantification was 
performed using the ΔΔCt method. 
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Symbol Description Accession number Forward primer  Reverse primer  
PPIA  Peptidylprolyl isomerase A NM_008084 CACTGTCGCTTTTCGCCGCTTG TTTCTGCTGTCTTTGGAACTTTGTCTGC 
Gli1 GLI-Kruppel family member GLI1 NM_010296 CCAGAGTCCAGCGGTTCAAGAG GTGGCGAATAGACAGAGGTAGGG 
Gli2 GLI-Kruppel family member GLI2 NM_001081125 GTTCCAAGGCCTACTCTCGCCTG CTTGAGCAGTGGAGCACGGACAT 
Gli3 GLI-Kruppel family member GLI3 NM_008130 AGCAAGCAGGAGCCTGAAGTCAT GTCTTGAGTAGGCTTTTGTGCAA 
Mycn v-myc myelocytomatosis viral related oncogene NM_008709 GGTGGCTGCTCCTGCTCGTG TCCTCTTCATCTTCCTCCTCGT 
Bmi1 Bmi1 polycomb ring finger oncogene  NM_007552 GATGGACTGACGAATGCTGGA TGTGAGGGAACTGTGGGTGAG 
FoxM1 Forkhead box M1 NM_008021 CACTTGGATTGAGGACCACTT GTCGTTTCTGCTGTGATTCC 
Shh Sonic hedgehog NM_009170 TTGCTTCCTCGCTGCTGGT ATGATGGCCGTCCTCATCC 
Ptch1 Patched homolog 1 NM_008957 CTGCGGCAAGTTTTTGGTTG AGGGCTTCTCGTTGGCTACAAG 
Smo Smoothened homolog NM_176996 CTGACTTTCTGCGTTGCAC CCAATGCTGCCCACGAAG 
App  Amyloid precursor protein NM_007471 GCAGCAGAACGGATATGAG GATGGGTAGTGAAGCAATGG 
 
Table4: List of the primers for real-time PCR expression analysis used in the 
present study. 
 
3.14 ANTISENSE EXPERIMENTS 
To silence the expression of Ptch1, experiments were performed by using an 
antisense oligonucleotide (5′-tcCTCCC AGTTTCCCAGTca-3′) and, as a control, 
a sense oligonucleotide (5′-tgACTGGGAAACTGGGAGga-3′). Both 
oligonucleotides (Sigma) were phosphorothioated to make them more resistant to 
the RNAase attack. Dissociated neurospheres were transfected by directly adding 
either phosphorothioate Ptch1 antisense or sense oligonucleotides into culture 
medium. Oligonuclotides were daily added (concentration in the culture medium: 
10 µM). 
 
3.15 METHYLCYTOSINE IMMUNOPRECIPITATION (mCIP) 
The mCIP method was adapted from previous studies (Keshet, Schlesinger et al. 
2006; Zhang, Du et al. 2006). The DNA was obtained from 4 x 106 cells using 
Blood and Cell DNA culture midi kit (Qiagen) according to the manufacturer’s 
instructions. Immunoprecipitation was performing using 15 µg of sonicated DNA 
with 5 µg of the mouse anti-methylcytosine monoclonal antibody (Calbiochem 
NA81) in 600 µl of buffer FB (10 mM Tris–HCl, pH 7.5, 50 mM NaCl, 1 mM 
EDTA) at 4°C overnight. A fraction of the recovered DNA was used for real-time 
PCR to determine the amount of the methylated Ptch1 promoter. Primer pairs for 
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real-time PCR analysis were designed to amplify two CpG islands (regions c and 
e; Fig. 23) already described (Takai and Jones 2002) and two non-CpG islands, as 
control regions (regions a and d; Fig. 24) of the mouse Ptch1 promoter. We 
additionally amplified the CpG-rich region described by Ecke et al. (Ecke, Petry 
et al. 2009) (region b; Fig. 24; see Table 5). 
 
3.16 CHROMATIN IMMUNOPRECIPIATATION (ChIP) 
Chromatin Immunoprecipitation (ChIP) is a type of immunoprecipitation 
experimental technique used to investigate the interaction between proteins and 
DNA in the cell. It aims to determine whether specific proteins are associated with 
specific genomic regions, such as transcription factors on promoters or other 
DNA binding sites. ChIP was performed as previously described (Weinmann and 
Farnham 2002). Briefly, protein and associated chromatin in a cell lysate were 
temporarily bonded by incubation with 1% formaldehyde for 30 min, the DNA-
protein complexes (chromatin-protein) were then sheared by sonication and DNA 
fragments associated with proteinswere selectively immunoprecipitatedusing 5 µg 
of anti-Acetyl-Histone H3 (06-599, Upstate) antibody. A preimmune serum was 
used as a negative control to determine the baseline of the nonspecific 
background. Dual crosslinking ChIP, a new variant of ChIP which allows the 
detection of chromatin components not directly binding to DNA, was performed 
as previously described (Liu, Tee et al. 2007) using 5 µg of the anti C-terminal 
APP antibody (A8717 Sigma-Aldrich) or IgG (sc-2027, Santa Cruz) as a negative 
control. The immunoprecipitated DNA samples were analyzed by real-time PCR 
to determine the amount of the histone H3 acetylation of the Ptch1 and Smo 
promoters and AICD binding to the Ptch1 and Smo promoters (Table 5 and 6). 
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Ptch1 Promoter 
Amplicon Primer name Sequence Position from start site 
a 
aF TTCCTTACCTCCTCCCTGAAACC -4929 
aR GCCAATCTGCCACCATCTTACC -4763 
b 
bF AGAGGGAAACAGTACACGCTTAGG -3332 
bR GCTGGTTGTGTGTATGGCATCG -3244 
c 
cF GCCGCCTTCAGGAATGTACTACG -2536 
cR CCCAGCCCTCATCACAGTGC -2427 
d 
dF CCTGGGTGGTCTCTCTACTTTGG - 918 
dR GCTGTCAGATGGCTTGGGTTTC - 798 
e 
eF AAGCAGCAGACAAGTGAAGGTTG +  257 
eR CGGACCTCAGACAGCCCTTTC +  332 
 
Table 5: List of the primers for real-time PCR Methylcytosine, Acetyl-histone H3 
immunoprecipitation and AICD Dual ChIP crosslinking analysis used in the present 
study. 
 
Smo Promoter 
Amplicon Primer name Sequence Position from start site 
a aF CGTCTTGCCCTTCATGCTCTC -3423 
 aR GGACTGTAGGATGCTGGAAGAAC -3232 
b bF GCAAGACATTGTGGATGTTGATAC -2461 
 bR CCTCCAGTACAAGGACCTTATCC -2374 
c cF CCCTGACATACCTGAGCGATAAAG -1129 
 cR TTACCTAGAACCCTGGTGGAGAAG - 943 
d dF ACAAAGAGCCCGAGTAAGGATGG + 561 
 dR GATTGCCTCAAGGTCTGAACACTG + 673 
 
Table 6: List of the primers for real-time PCR Acetyl-histone H3 immunoprecipitation 
and AICD Dual ChIP crosslinking analysisused in the present study. 
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3.17 STATISTICAL ANALYSIS 
Results are presented as the mean ± standard error (SE) of the mean. Statistical 
significance was assessed by two-way analysis of variance (ANOVA), followed 
by Bonferroni’s post hoc test or by the two-tailed Student’s t-test. A probability 
level of P <0.05 was considered to be statistically significant. 
 76 
4. RESULTS 
 
4.1 Neuronal precursor cultures from Ts65Dn mice exhibit the 
same proliferation impairment as the in vivo condition 
The first aim of our study was to evaluate whether neuronal precursors (NPCs) 
from the subventricular zone and from the dentate gyus of trisomic mice exhibit 
the same proliferation defects observed in vivo. Neural stem and progenitor cells 
are maintained and expanded as spherical aggregates termed “neurospheres”. 
Primary cultures from both euploid and Ts65Dn mice formed typical 
neurospheres (Fig. 14A). The growth kinetics of NPCs from the SVZ was 
monitored over time. While at day 1 in vitro (DIV1) there was no difference in the 
morphology and number of neurospheres of Ts65Dn and euploid mice; the 
diameter of trisomic neurospheres was significantly smaller than that of the 
euploid counterpart starting from DIV3 (Fig. 14A and B), suggesting defective 
proliferation. In agreement with this finding, trisomic neurospheres exhibited a 
reduced BrdU incorporation rate versus the control counterpart (-25%; Fig. 14C). 
Furthermore, proliferation rate through BrdU incorporation was evaluated in 
NPCs from the hippocampus of trisomic and euploid mice. Results showed a 
reduced BrdU staining in trsisomic neurospheres just like NPCs from the SVZ (-
30%; Fig. 14D).  
In order to establish whether the reduced growth and number of BrdU-positive 
cells observed in trisomic neurospheres could be attributed to an increased cell 
death, we estimated cleaved caspase-3 immunostaining and pyknotic appearance 
of the nuclei of dying cells (data not shown), but no difference in apoptotic cell 
death was observed between control and trisomic neurospheres derived from both 
the SVZ and hippocampus.  
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We recently obtained evidence that in fetuses with DS as well as in the Ts65Dn 
mouse model cell proliferation is impaired most likely due to elongation of the 
cell cycle (Contestabile, Fila et al. 2007; Contestabile, Fila et al. 2009).The total 
duration of the cell cycle (Tc) and the duration of the S phase (Ts) can be 
estimated by BrdU-cumulative LI (Kornack and Rakic 1998). According to this 
protocol, successive cohorts of cells entering the S phase are labeled with BrdU at 
consecutive time intervals (typically, each 2 hr). Maximum LI corresponds to the 
growth fraction (GF) and the time at which the LI reaches a maximum 
corresponds to Tc-Ts. Then, we analyzed the we evaluated total cell cycle length 
(TC), S-phase length (TS) and GF by BrdU-cumulative labeling in NPCs from 
Ts65Dn mice (Fig. 15). Cell cycle analysis revealed that in control neurospheres, 
the cell cycle length was 29.56 h. In contrast, in Ts65Dn mice, the cell cycle 
length was 59.02 h, which corresponds to a difference of +100%. The length of 
the S-phase showed a small but significant increase in trisomic versus control 
neurospheres Trisomic neurospheres had a GF similar to the euploid counterpart, 
indicating no difference in the relative size of the population of proliferating 
NPCs.  
 
Figure 14:. Cell proliferation in neurospheres from euploid and Ts65Dn 
mice.  
(A) Phase-contrast images of free-floating neurospheres at day 3 (DIV3) or 
day 6 (DIV6) in vitro from P2 euploid or Ts65Dn mice. Scale bar: 50 mm. 
(B) Mean diameter of neurospheres derived from P2 euploid or Ts65Dn 
mice (n=4 per group) at different DIV. (C-D) Cell proliferation in 
neurospheres from the SVZ and hippocampus of euploid and Ts65Dn mice. 
LI, defined as percentage of BrdU-positive cells over total cell number, was 
determined for euploid and trisomic neurospheres. At DIV4, BrdU (10 mM) 
was added for the last 16 h and thereafter cells were processed for BrdU 
immunocytochemistry. Results are expressed as percentage of control 
values and were obtained from neurosphere cultures derived from euploid 
(n=6) and Ts65Dn (n=6) mice.  
.  
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Figure 15: Cell cycle analysis of neurospheres from euploid and Ts65Dn 
mice. Cumulative labelling indexes in control (black circles) and trisomic 
(orange squares) neurospheres as function of time after BrdU administration 
(time 0). Neurospheres, at the fourth passage in culture, were incubated with 
10 µM BrdU for increasing time intervals (1.5, 3.0, 4.5, 6.0, 24, 48 and 72 h) 
and processed for BrdU immunofluorescence cytochemistry. Parameters used 
for cell cycle length measurement are indicated in Methods.  
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After DNA synthesis, this takes place during the S phase of cell cycle, cells pass 
through the G2 phase before undergoing division in the M phase. Since the G2 
phase is a critical step for cell cycle progression, we have sought to obtain 
information on the relative size of the population in the G2 versus M phase of cell 
cycle, by labeling the proliferating cells with an antibody against phosphorylated-
histone-H3 (pHH3). This marker is expressed during late G2 and mitosis 
(anaphase to telophase) and its nuclear pattern allows one to discriminate cells 
that are in the G2 and M phases of cell cycle (see Methods; (Hendzel, Wei et al. 
1997). We found that trisomic neurospheres had a larger percentage of NPCs in 
G2 and a similar percentage of cells in the M-phase compared with controls (Fig. 
16A-B). Evaluation of the length of the G2- and M-phases (see Materials and 
Methods) indicated a notable elongation (+159%) of the G2-phase in trisomic 
neurospheres compared with controls, while the length of the M-phase was 
unchanged. There are no specific markers for the G1-phase of the cell cycle. Thus, 
we estimated its length by subtracting from the total cell cycle length the summed 
length of the remaining phases (S, G2, M). We found that in trisomic 
neurospheres, the duration of the G1-phase was significantly larger (+112%) than 
controls. 
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Figure 16: (A) Number of cells in G2- and M-phases of the cell cycle, expressed 
as percentage of total number of cells positive for pHH3, evaluated in euploid 
and trisomic neurospheres. (B) Images of pHH3-positive cells in euploid and 
Ts65Dn neurospheres. Cells in G2 exhibit a  discontinuous pHH3 nuclear 
staining (arrowhead), cells in the early M-phase exhibit a homogeneously 
condensed pattern (arrow).  
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4.2 Neuronal precursor cultures from Ts65Dn mice exhibit the 
same defective neuronal differentiation as the in vivocondition 
Recent evidence shows that not only neuron generation but also differentiation is 
heavily compromised in DS (Contestabile, Fila et al. 2007; Contestabile, Fila et 
al. 2009; Guidi, Ciani et al. 2011). We attempted to determine whether NPCs 
from Ts65Dn mice have defective neuronal differentiation similarly to the in vivo 
condition (Contestabile, Fila et al. 2007). For this purpose we compared the 
number of neurons and astrocytes produced by trisomic versus euploid 
neurospheres. After 7 days in culture conditions that favor differentiation 
(Reynolds and Weiss 1992), we found that the number of neurons (β-tubulin III-
positive cells) generated from trisomic neurosphereswas notably smaller 
compared with controls (Fig. 17A-C), while the number ofastrocytes (GFAP-
positive cells) was larger (Fig. 17B-C). 
These results indicate that cultures of trisomic NPCs are a suitable model to study 
the mechanisms underlying neurogenesis impairment in DS because they exhibit a 
reduced proliferation rate, elongation of the cell cycle and impaired acquisition of 
a neuronal phenotype, similarly to the in vivo condition (Chakrabarti, Galdzicki et 
al. 2007; Contestabile, Fila et al. 2007; Contestabile, Fila et al. 2009; Bianchi, 
Ciani et al. 2010) 
 
 83 
 
 
0
10
20
30
40
50
60
70 Euploid
Ts65Dn
%
 G
F
A
P
-p
o
si
ti
ve
 c
el
ls
0
10
20
30
40
50
60
70
%
!
-T
u
b
 I
II
-p
o
si
ti
ve
 c
el
ls
A B !-Tubulin III GFAP 
Euploid Ts65Dn 
C 
!-Tub-GFAP-Hoechst 
**
 
* 
 
Figure 17: Differentiation of NPCs from euploid and Ts65Dn mice. 
A,B: Percentages of !-Tubulin III (A) and GFAP (B) positive cells after 7 
days of differentiation. *P<0.05, **P<0.01 (two tailed t-test). (C): 
Representative double-fluorescence images of cells dissociated from 
neurospheres and immunopositive for !-tubulin III (red) and GFAP 
(green). Cell nuclei were stained by Hoechst dye (blue).  
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4.3 Deranged expression of genes belonging to the Shh pathway in 
neural precursors from Ts65Dn mice 
It has recently been shown that the reduced proliferation of cerebellar granule cell 
precursors from Ts65Dn mice is related to an attenuated response to Shh (Roper, 
Baxter et al. 2006), suggesting an alteration in the molecular cascade of this 
pathway in DS. 
As first step, we performed a gene expression study, by quantitative real time 
PCR (RT–qPCR), to establish whether genes known to be involved in the Shh 
pathway exhibited an altered expression in trisomic NPCs.  We found that the Gli 
family members Gli1, Gli2 and Gli3, which are transcription factors functioning 
as Shh effectors, showed a significant down-regulation (-42, -46 and -60%, 
respectively) in trisomic neurospheres (Fig. 18A). 
Looking at the expression of Gli target genes, we found that MycN and Bmi1 
were greatly down-regulated (-70 and -40%, respectively) in trisomic 
neurospheres (Fig. 18B).Additionally, the expression of FoxM1, an indirect Gli 
target that promotes cell cycle progression at the G2/M-phase transition, was also 
down-regulated (Fig. 18B). These observations clearly indicate derangement of 
the Shh pathway in NPCs from Ts65Dn mice.Activation of the Shh pathway starts 
with the binding of Shh to its receptor Patched1 (Ptch1), which releases the 
pathway activator Smoothened (Smo) by the Ptch1-dependent inhibition, leading 
to activation of GLI transcription factors.We next examined the expression of the 
membrane associated receptors Smo and Ptch1 and the Shh ligand in euploid and 
trisomic neurospheres. Whereas no significant differences were observed in the 
expression of Shh and Smo, we found a notable up-regulation of Ptch1 in trisomic 
neurospheres (Fig. 18C).  
Western blot and immunocytochemistry analyses showed a significantly higher 
expression of Ptch1 in trisomic neurospheres also at the protein level (Fig. 19A 
and C). Similar results were obtained in trisomic neurospheres derived from the 
hippocampus (Fig. 19B) suggesting that an increased expression of Ptch1 may be 
the common molecular denominator of the Shh pathway derangement in trisomic 
NPCs. 
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Figure 18: Expression of Shh pathway genes in neurospheres from euploid and 
Ts65Dn mice. (A-C) Quantification by RT–qPCR of Gli1, Gli2 and Gli3 (A); MycN, 
Bmi1 and FoxM1 (B); Shh, Ptch1 and Smo (C) expression in neurospheres from 
Ts65Dn (n=6) and euploid (n=6) mice, given as percentage of the control condition. 
*P<0.05, **P<0.01, ***P<0.001 (two tailed t-test).  
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Figure 19: (A-B) Western blot analysis of Ptch1 expression in 
neurospheres from the SVZ and hippocampus of Ts65Dn (n=4) and 
euploid (n=4) mice. Protein expression was normalized to !-actin 
content. Values represent mean±SE. ? P< 0.05, ?? P< 0.01, ??? P< 
0.001 (two-tailed t-test). (C) Representative images of neurospheres from 
an euploid and a Ts65Dn mouse processed for Ptch1 fluorescence 
immunocytochemistry. Cell nuclei were stained by Hoechst dye (blue). 
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4.4 Neural precursors from Ts65Dn mice do not respond to Shh 
Starting from the recent evidence that cerebellar granule cell precursors from 
Ts65Dn mice do not respond to the Shh stimulus (Roper, Baxter et al. 2006), we 
decided to evaluate also the response of NPCs from the SVZ to the Shh. 
Administration of Shh for 72 h induced a proliferation increase in neurospheres 
from control mice, but no increase in neurospheres from Ts65Dn mice (Fig. 20A), 
indicating that trisomic NPCs from the SVZ are not responsive to Shh similarly to 
cerebellar granule cell precursors. In control neurospheres, treatment with Shh in 
the presence of cyclopamine, an antagonist of Smo, prevented the proliferation 
increase induced by Shh and, additionally, caused a decrease (-20%) in cell 
proliferation compared with the untreated condition (Fig. 20A). This suggested a 
basal activation state of the Shh pathway, probably due to paracrine production of 
Shh, as previously reported (Osterberg and Roussa 2009). In contrast, co-
treatment with Shh and cyclopamine had no effect on cell proliferation in trisomic 
neurospheres. A series of small molecule agonists, that cross the blood–brain 
barrier, triggers Shh pathway activity by binding to and activating the Smo 
component of the Shh response pathway (Frank-Kamenetsky, Zhang et al. 2002); 
(Chen, Taipale et al. 2002). One of these molecules, SAG (smoothened agonist) is 
an agonist for Smo that relieves the inhibitory effect of Ptch1 on Smo (Chen, 
Taipale et al. 2002). Incubation of neurospheres with SAG enhanced cell 
proliferation in euploid (+23%) and trisomic (+56%) NPCs (Fig. 20A). The latter 
finding clearly indicates that the Shh pathway downstream to Smo is functional in 
trisomic NPCs, which suggests that its impairment is upstream to Smo. As 
expected, co-exposure of cells to SAG and cyclopamine prevented the 
proliferation increase induced by SAG alone in both euploid and Ts65Dn 
neurospheres (Fig. 20A). 
To further confirm that the Shh pathway is impaired in trisomic NPCs upstream to 
Smo, we examined Gli1, whose expression is dependent on Shh pathway 
activation. While both Shh and SAG treatments significantly increased Gli1 
expression in control neurospheres, in trisomic neurospheres SAG but not Shh 
treatment increased Gli1 expression (Fig. 20B). These data suggest that NPCs 
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from Ts65Dn mice are unable to respond to Shh due to up-regulation of Ptch1, 
which by inhibiting Smo, makes the Shh pathway functionally inactive. 
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4.5 Silencing of Ptch1 expression restores proliferation in neural 
precursors from Ts65Dn mice 
According to the previous experiments, we found that NPCs from the trisomic 
NPCs were not able to respond to the Shh stimulus because of an alteration in the 
Shh pathway, upstream to Smo, due to an aberrant overexpression of Ptch1. 
In this sense we further investigate about the role of Ptch1 in the impaired 
proliferation of NPCs from Ts65Dn mice, reducing its expression by using an 
antisense oligonucleotide (AS) directed against it. Antisense oligonucleotides are 
single strands of DNA or RNA that are complementary to a chosen sequence. 
Antisense DNA can be used to target a specific, complementary RNA, preventing 
protein translation. AS treatment reduced Ptch1 expression in both euploid and 
trisomic neurospheres (-60 and -40%, respectively) and, in trisomic neurospheres, 
Ptch1 expression became similar to that of the untreated euploid counterpart (Fig. 
21A). Along with the reduction in Ptch1 expression, there was an increase in cell 
proliferation in both euploid and trisomic neurospheres (+20% and +39%, 
respectively) (Fig. 21B).Comparison of AS-treated trisomic neurospheres with 
untreated euploid neurospheres showed no proliferation differences (Fig. 21B), 
indicating that inhibition of Ptch1 expression had completely restored cell 
proliferation in trisomic NPCs. Treatment with a sense oligonucleotide, as a 
negative control, had no effect on Ptch1 expression and cell proliferation (data not 
shown).  
Figure 20: Response to Shh in neurospheres from euploid and Ts65Dn mice. (A) 
LI was determined for neurospheres from euploid (n=3) and Ts65Dn (n=3) mice. 
Neurospheres were treated with Shh (3 µg/ml), cyclopamine (Cyc; 10 µg/ml), SAG 
(250 nM), Shh plus cyclopamine or SAG plus cyclopamine for 72 h starting from 
DIV1. (B) Quantification by RT–qPCR of Gli1 expression in neurospheres treated 
with Shh (3 µg/ml) or SAG (250 nM) for 24 h starting at DIV4 (three Ts65Dn and 
three euploid mice). Data are given as percentage of the euploid untreated 
condition. The scheme on the right shows that Shh drives the Shh pathway by 
removing the inhibition exerted by Ptch1 on Smo, and the negative and positive 
effect exerted by Cyc and SAG, respectively, on Smo. Values represent mean+SE. 
The asterisk indicates a significant difference in euploid and trisomic neurospheres 
versus euploid untreated neurospheres. The # indicates a significant difference of 
trisomic treated neurospheres versus trisomic untreated neurospheres. ∗ P<0.05; 
∗∗ P<0.01; ∗∗∗ P<0.001 (Bonferroni’s test after ANOVA). 
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Figure 21: Effect of Ptch1 silencing on cell proliferation in neurospheres from 
euploid and Ts65Dn mice. (A) Quantification of Ptch1 immunofluorescence in 
neurospheres from Ts65Dn and euploid mice after 24 h exposure to a Ptch1 
antisense oligonucleotide (10 µM) starting at DIV3 (left panel). Representative 
example of a western blot showing the Ptch1 band in cell extracts from trisomic 
and euploid neurospheres after 24 h exposure to a Ptch1 antisense oligonucleotide 
(right panel). The partial silencing of Ptch1 by antisense oligonucleotides is shown 
in the scheme on the right. (B) LI, defined as percentage of BrdU-positive cells 
over total cell number, was determined for euploid and trisomic neurospheres 
treated with Ptch1 antisense oligonucleotides (10 µM) for 72 h after DIV1. The 
asterisks indicate a significant difference of euploid and trisomic neurospheres 
versus euploid untreated neurospheres. ?? P<0.01, ??? P<0.001 (Bonferroni’s test 
after ANOVA). 
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We next examined whether inhibition of Ptch1 expression made trisomic NPCs 
responsive to Shh. After treatment with AS, trisomic neurospheres became 
responsive to Shh and underwent a proliferation increase similarly to the euploid 
counterpart (Fig. 22: L plus AS). This finding demonstrates that inhibition of 
Ptch1 overexpression completely restores the response of trisomic NPCs to the 
Shh-mitogenic stimulus. Addition of a higher concentration of Shh to trisomic 
NPCs increased cell proliferation to the same level as treated-euploid NPCs (Fig. 
22: H), suggesting that stimulation of the Shh pathway with a higher dose of Shh 
can overcome the inhibitory effect exerted by Ptch1 overexpression on Smo and 
therefore the mitogenic deficit in trisomic NPCs. 
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Figure 22: (C) LI determined for euploid and trisomic neurospheres treated with either 
Shh alone (3 µg/ml; L and 6 µg/ml; H) or Shh (3 µg/ml; L) plus Ptch1 antisense 
oligonucleotides (10 µM) for 72 h after DIV1. Data are given as percentage of the euploid 
untreated condition, are expressed as mean±SE (four euploid and four Ts65Dn mice). 
The asterisks indicate a significant difference of euploid and trisomic neurospheres versus 
euploid untreated neurospheres. ?? P<0.01, ??? P<0.001 (Bonferroni’s test after 
ANOVA). 
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4.6 Ptch1 promoter is highly acetylated in neural precursors from 
Ts65Dn mice 
Gene expression is finely regulated by epigenetic mechanisms of methylation and 
acetylation. These epigenetic mechanisms have an important regulatory role in 
gene expression and act by inhibiting and favoring gene transcription, respectively 
(Vaissiere, Sawan et al. 2008).There is evidence that epigenetic modification of 
the PTCH1 promoter significantly affect PTCH1 gene expression in various 
disease conditions (Cretnik, Musani et al. 2007; Pritchard and Olson 2008). For 
this reason, we sought to determine whether DNA methylation and/or histone 
acetylation can regulate the activity of the Ptch1 promoter in NPCs. In this sense, 
we treated neurospheres with either 5-Aza-2′-Deoxycytidine (AZA), an inhibitor 
of DNA methyltransferase or Trichostatin A (TSA), an inhibitor of histone 
deacetylase. While AZA treatment induced a small increase (2–3-folds) in Ptch1 
expression, TSA treatment highly increased (20–22-folds) Ptch1 expression in 
both control and trisomic neurospheres (Fig. 23). This suggests that DNA 
methylation of the Ptch1 promoter is not a major determinant of Ptch1 regulation, 
while histone acetylation appears to be an important epigenetic mechanism that 
regulates Ptch1 expression in NPCs.  
We next attempt to establish whether trisomic neurospheres exhibited a different 
Ptch1 promoter methylation and/or acetylation status versus euploid neurospheres. 
To this purpose, we employed methylcytosine immunoprecipitation (mCIP) and 
acetyl-histone H3 immunoprecipitation (chromatin immunoprecipitation (ChIP)) 
assays. In the promoter region of Ptch1close to the start site, there are two CpG 
islands (Fig. 24: c, e) and a CpG-rich region (Fig. 23: b) (Takai and Jones 2002). 
The relative enrichment of methylated DNA in the CpG islands (c, e) and in the 
CpG-rich region (b), normalized to the enrichment of two control regions (non-
CpG-rich regions; a, d) is shown in Figure 24 (upper histograms). It can be noted 
that, unlike the CpG-rich region, the CpG islands of the Ptch1 promoter were 
unmethylated, both in control and trisomic NPCs. In the CpG-rich region of 
trisomic NPCs, the methylation status was slightly, though not significantly, 
higher than the euploid counterpart (Fig. 24: b). On the contrary, we found that 
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the histone H3 acetylation was stronger in all these regions (a–e) in trisomic 
versus euploid NPCs (Fig. 24). More specifically, hyper-acetylation occurred at 
those promoter regions proximal to the transcription start site (c, d and e in Fig. 
24). These data indicate that in trisomic NPCs the Ptch1 promoter is highly 
acetylated and provide a plausible explanation for why Ptch1 is overexpressed in 
trisomic NPCs. No difference in the acetylation status of the Smo promoter was 
observed between euploid and trisomic neurospheres (Table 7) suggesting that the 
increased acetylation in trisomic neurospheres is peculiar for the Ptch1 promoter. 
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Figure 23: Methylation and acetylation status of the Ptch1 promoter 
in neurospheres from euploid and Ts65Dn mice.  
(A) Quantification by RT–qPCR of Ptch1 expression in neurospheres from 
Ts65Dn (n . 4) and euploid (n . 4) mice treated with either 5-Aza-2!-
deoxycytidine (AZA, 5 µM) or TSA (150 nM) for 72 h after DIV1. Data, 
given as percentage of the euploid untreated condition, are expressed as 
mean+SE. The asterisks indicate a significant difference between euploid 
and trisomic neurospheres versus euploid untreated neurospheres. ?? 
P<0.01, ??? P<0.001 (Bonferroni’s test after ANOVA). 
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Acetyl-histone H3 immunoprecipitation (ChIP)  
 
 
Amplicon 
 
a b 
 
c 
 
d 
Euploid (n=3) 12.8±0.2 20.9±1.5 123±11 344±120 
      
Ts65Dn (n=3) 12.4±0.3 14.3±5.0 126±9.0 522±44 
 
 
AICD immunoprecipitation (ChIP) 
 
 
Amplicon 
 
a b 
 
c 
 
d 
Euploid (n=4) 1.0±0.19 2.07±1.2 1.11±0.33 1.72±0.78 
      
Ts65Dn (n=4) 1.0±0.12 0.79±0.53 0.70±0.62 1.51±0.21 
      
Euploid 
+ DAPT (n=3) 1.0±0.42 0.84±0.48 0.37±0.57 0.51±0.86 
      
Ts65Dn 
+DAPT (n=3) 1.0±0.33 0.96±0.28 2.21±0.64 1.55±0.44 
 
Figure 24: Detailed methylation and acetylation status of the Ptch1 promoter in 
neurospheres from euploid and Ts65Dn mice.  
The mCIP assay (upper panels) was performed with an antimethylcytosine 
antibody and primers targeting amplicons a–e in neurospheres at DIV4 from 
trisomic (n . 4) and euploid (n . 4) mice. Fold enrichment of the Ptch1 gene 
promoter by anti-methylcytosine antibody was calculated by dividing the PCR 
product from amplicons b, c or e by the PCR product from amplicons a and d that 
represent non-CpG control regions. The ChIP assay (middle panels) was 
performed using an anti-Acetyl-Histone H3 and the same primers used for the 
mCIP. Fold enrichment of a given DNA region immunoprecipitated with the anti-
Acetyl-Histone H3 antibody was calculated as the ratio between the enrichment 
obtained with the specific antibody compared with pre-immune serum. Values 
represent mean?SE. * P<0.05, ** P<0.01, *** P<0.001 (two-tailed t-test).  
The lower panel shows a schematic representation of the mouse Ptch1 gene 
promoter. The diagram includes: transcription start site (black arrow); target 
regions of PCR primers for quantitative ChIP assay (amplicons a–e: gray boxes); 
CpG-rich region and CpG islands (black boxes) 
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4.7 Triplicated amyloid precursor protein increases Ptch1 
expression through AICD 
In Ts65Dn mice, there is an extra copy of the gene coding for the amyloid 
precursor protein (APP), which led to a greater expression of this protein in the 
Ts65Dn brains. (Holtzman, Santucci et al. 1996). 
APP undergoes extensive post-translational modification including proteolytic 
processing to generate peptide fragments.  APP is commonly cleaved by proteases 
of the secretase family; α-secretase, β-secretase and γ-secretase. It has been 
recently shown that the APP intracellular domain (AICD), that is generated from 
the APP protein through sequential proteolysis by α- and γ-secretases, up-
regulates PTCH1 expression in neuroblastoma cells (Raychaudhuri and 
Mukhopadhyay). AICD has been reported to form a complex with Fe65 and the 
histone acetyltransferase Tip60 and cause transcriptional activation by increasing 
the acetylation status of the chromatin (Cao and Sudhof 2001; Kim, Kim et al. 
2004). Quantification of the APP gene in trisomic NPCs showed that its 
expression was very close to the theoretical 1.5-fold increase expected from the 
presence of one extra copy of APP (Fig. 25A). In parallel with these findings, 
AICD had significantly increased levels in the nucleus of trisomic NPCs (Fig. 
25B).  
We next examined the potential interaction between AICD and the Ptch1 
promoter, by ChIP analysis. Crosslinked chromatin extracts from trisomic and 
euploid neurospheres, immunoprecipitated with an antibody against AICD, 
showed the presence of AICD binding to the three regions of the Ptch1 promoter 
with highest acetylation (Fig. 24C: c–e). In contrast, in euploid neurospheres, the 
levels of chromatin extracts immunoprecipitated with AICD were similar to the 
background (=1), indicating the absence of AICD binding to the Ptch1 promoter 
Table 7: Acetyl-histone H3 and AICD immunoprecipitation analysis of the Smo 
promoter 
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(Fig. 24C). We treated neurospheres with DAPT, an inhibitor of γ-secretase, in 
order to reduce AICD formation and found that this treatment reduced the binding 
of AICD to the Ptch1 promoter in trisomic neurospheres (Fig. 24C). In contrast, 
the binding of AICD to the Smo promoter was similar in euploid and trisomic 
neurospheres under basal conditions and after treatment with DAPT (Table 7). 
Treatments with DAPT reduced Ptch1 expression in trisomic neurospheres (Fig. 
26D). The same results were obtained with Compound E, another inhibitor of γ-
secretase (Fig. 26D). These data provide evidence for a relationship between 
AICD levels and Ptch1 expression in trisomic neurospheres. 
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Figure 25: APP and AICD expression in neurospheres from euploid and 
Ts65Dn mice. (A) Quantification by RT–qPCR of APP expression in trisomic 
and euploid neurospheres at DIV4. Values represent mean+SE. ?? P , 0.01 
(two-tailed t-test).  
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Figure 26: AICD binding to Ptch1 promoter in neurospheres from euploid 
and Ts65Dn mice. (A) ChIP assay using an anti-C-terminal APP antibody 
which recognizes AICD and the same primers used for the mCIP (amplicons a–
e are the same as Fig. 24) in neurospheres from trisomic (n = 4) and euploid (n 
= 4) mice in the presence of absence of the !-secretase inhibitor DAPT (10 
µM; 48 h). Fold enrichment of a given DNA region of the mouse Ptch1 gene 
promoter was calculated as the ratio between the enrichment obtained with the 
specific antibody compared with a non-specific IgG (control). (B) 
Quantification of Ptch1 immunofluorescence in neurospheres from Ts65Dn and 
euploid mice after 48 h exposure to the !-secretase inhibitor DAPT (10 µM) or 
Compound E (Comp. E; 1 nM), starting at DIV1. The asterisk indicates a 
significant difference of euploid and trisomic neurospheres versus euploid 
untreated neurospheres. The # indicates a significant difference of trisomic 
treated neurospheres versus trisomic untreated neurospheres. ? P , 0.05; ?? P , 
0.01; ??? P , 0.001 (Bonferroni’s test after ANOVA). 
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4.8 In vivo Ptch1 overexpression in the trisomic brain 
We next sought to establish whether the reduced proliferation rate of trisomic 
NPCs was accompanied by a high expression of Ptch1also in the in vivo 
condition. We found that neonate (P2) Ts65Dn mice had remarkably fewer 
proliferating cells (BrdU-positive cells) in the SVZ (euploid: 22260±1979, 
Ts65Dn: 9106±2271; P<0.01) and in the hippocampal dentate gyrus (DG; 
euploid: 6320±2616, Ts65Dn: 2154±670; P<0.05) compared with control mice, as 
previously observed in P15 adult trisomic mice (Bianchi, Ciani et al. 2010; 
Bianchi, Ciani et al. 2010). We first analysed Ptch1 expression in whole brain 
homogenates derived from neonate Ts65Dn mice and found no difference vs 
euploid mice (data not shown).  However, in view of the small number of 
precursor cells compared with the number of neurons and glial cells forming the 
brain, a possible up-regulation of Ptch1 confined to neuronal precursors may be 
undetectable in whole brain homogenates. Consequently, we analyzed Ptch1 
expression by fluorescence immunohistochemistry. Consistently, with the up-
regulation of Ptch1 observed in vitro (Fig. 19A, B and C), we found that in the 
SVZ and DG of Ts65Dn mice, Ptch1 had a considerably higher expression 
compared with that of euploid mice (Fig. 27A–D). No difference in Ptch1 
expression was found in the striatum and prefrontal cortex of Ts65Dn versus 
euploid mice (Fig. 27A and B). These data suggest that overexpression of Ptch1 in 
trisomic mice takes place specifically in proliferating neural precursors.  
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Recently, we found that human fetuses with DS had remarkably fewer 
proliferating cells in all germinal zones of the hippocampal region (Contestabile, 
Fila et al. 2007; Guidi, Bonasoni et al. 2008). To establish whether, similarly to 
the mouse model, fetuses with DS exhibit PTCH1 overexpression, we examined 
the expression pattern of PTCH1 in the ventricular zone of the hippocampus and 
parahippocampal gyrus (PHG) (Fig. 28A). At the examined ages (17–21 weeks), 
the ventricular zone of the hippocampus and PHG was formed by several rows of 
actively dividing cells (Guidi, Bonasoni et al. 2008). Immunohistochemical 
analysis showed that PTCH1 had a larger expression in the ventricular zone of the 
hippocampus (+50%) and PHG (+88%) of fetuses with DS (Fig. 28B), indicating 
that a defect in PTCH1 expression is present also in neuronal precursor cells of 
human subjects with DS. 
 
Figure 27: Ptch1 expression in Ts65Dn mice. (A) Examples of Ptch1 fluorescence 
immunohistochemistry at the level of the rostral part of the lateral ventricle of a P2 
euploid and a Ts65Dn mouse. Images were taken in the regions labeled with the 
corresponding numbers in the section shown in the middle (1, neocortex; 2, striatum; 
3, roof of the lateral ventricle; 4, lateral wall of the lateral ventricle). Calibrations: 
low magnification image = 200 µm; higher magnification images = 40 µm. (B) 
Quantification of Ptch1 expression in euploid and Ts65Dn mice. (C) Examples of 
Ptch1 fluorescence immunohistochemistry at the level of the hippocampal DG (left 
panels). Scale bar: 60 µm. (D) Quantification of Ptch1 expression in the granule cell 
layer (GR) and hilus (SGZ plus hilus proper) of euploid and Ts65Dn mice. Data (in B 
and D), given as percentage of the euploid condition, are expressed as mean?SE 
(three euploid and three Ts65Dn mice). * P<0.05, ** P<0.01, *** P<0.001 (two-
tailed t-test). GR, granule cell layer; H, hilus; I, layer one; II layer two; LW, lateral 
wall of the lateral ventricle; ML, medial wall of the lateral ventricle; NC, neocortex; 
ROOF, roof of the lateral ventricle; ST, striatum. 
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Figure 28: PTCH1 expression in control and DS human fetuses. (A) 
Examples of PTCH1 fluorescence immunohistochemistry at the level of the 
hippocampal region of a control (GW 19) and a DS (GW 19) fetuses. 
Images were taken in the regions labeled with the corresponding numbers 
in the Nissl-stained section shown in the middle. Calibrations: low 
magnification image = 1000 µm; higher magnification images = 50 µm. 
DG, dentate gyrus; FI, fimbria; GM, germinal matrix; HIPP, 
hippocampus; PHG, parahippocampal gyrus; TH, temporal horn of the 
lateral ventricle. (B) Quantification of PTCH1 expression in control and 
DS fetuses. Data, given as percentage of the control condition, are 
expressed as mean±SE (three control and three DS fetuses). ?? P< 0.01 
(two-tailed t-test). 
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5. DISCUSSION 
 
5.1 Cultured trisomic NPCs exhibit the same neurogenesis defects 
as the in vivo condition. 
Analysis of cultures of NPCs from Ts65Dn mice showed that they exhibited a 
significantly reduced proliferation rate compared to the euploid counterpart. 
Furthermore, we demonstrated that it is due to an elongation of the cell cycle, 
with a particularly prominent elongation of the G1- and G2-phases. Finally, 
similarly to previous observation in vivo (Contestabile, Fila et al. 2007; 
Contestabile, Fila et al. 2009), trisomic NPCs exhibited an impaired acquisition of 
a neuronal phenotype.  
These findings indicate that cultures of NPCs from the Ts65Dn mouse replicate 
the same proliferation/differentiation defects observed in vivo (Contestabile, Fila 
et al. 2007; Contestabile, Fila et al. 2009), suggesting that the in vitro system 
faithfully recapitulates the molecular mechanisms that underlie neurogenesis 
impairment in DS. Our findings are in line with recent studies that have 
demonstrated proliferation and differentiation impairment in cultures of 
embryonic NPCs from the Ts1Cje mouse model (Moldrich, Dauphinot et al. 
2009) and from fetuses with DS (Bahn, Mimmack et al. 2002; Bhattacharyya, 
McMillan et al. 2009) 
 
5.2 Impairment of the Shh pathway characterizes trisomic NPCs 
Accumulating evidence has highlighted the importance of Shh signaling for 
neuronal precursor proliferation. Shh treatment of cultured neural stem cells 
derived from the SVZ and hippocampus has been shown to increase proliferation 
of multipotent neural stem cells (Lai, Kaspar et al. 2003; Palma, Lim et al. 2005). 
Additionally, while viral delivery of Shh increases proliferation of cells in the 
hippocampal subgranular zone, conditional knockout of Smo (a membrane protein 
that mediates the Shh effects) results in a decrease in neural precursor 
proliferation and neurosphere formation (Lai, Kaspar et al. 2003; Machold, 
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Hayashi et al. 2003). Previous research demonstrated that cerebellar granule cell 
precursors of Ts65Dn mice had a deficit in the Shh-induced mitogenic response 
versus the euploid counterpart (Roper, Baxter et al. 2006). Due to the very wide 
brain expression of the Shh pathway, we hypothesized that trisomic NPCs from 
different neurogenic regions may exhibit a similar Shh response deficit, which 
would explain the widespread neurogenesis impairment that characterizes the DS 
brain. We indeed found a deficit in the Shh-induced mitogenic response in NPCs 
derived from both the SVZ and hippocampus of Ts65Dn mice. The response 
deficit to Shh in cerebellar granule cells (Roper, Baxter et al. 2006), SVZ and 
hippocampal precursors confirms our hypothesis that Shh pathway impairment 
may be a common mechanism that underlies the proliferation deficit of trisomic 
neuronal precursors. A recent work in the Ts65Dn mouse demonstrated that 
neural crest progenitors giving origin to the mandible have a deficient mitotic 
response to Shh (Roper, VanHorn et al. 2009). In addition, recent evidence in 
human fetuses with DS shows that aberrant lymphatic endothelial cells exhibit an 
increased Shh expression (de Mooij, van den Akker et al. 2009). These findings 
suggest that the trisomic condition is characterized by a widespread alteration of 
the Shh pathway that may involve peripherical tissues.  
 
5.3 Ptch1 overexpression underlies impairment of Shh-induced 
mitogenic response of trisomic NPCs  
The molecular and intracellular interactions that transduce the mitogenic response 
to Shh are not completely understood but are believed to include the nuclear 
translocation of cytoplasmic Gli1 with increased transcription of MycN, cyclin D, 
Ptch1 and Gli1 itself (Ding, Fukami et al. 1999; Kenney, Cole et al. 2003). We 
found here that genes known to be involved in the Shh pathway exhibited an 
altered expression in trisomic NPCs. While most of the genes downstream to Shh 
signaling (including the three Gli proteins and MycN) were down-regulated, there 
was a large increase in Ptch1 expression. A defining characteristic of the Shh 
pathway is the antagonistic relationship between Shh and Ptch1. Activation of the 
Shh pathway starts with the binding of Shh to its receptor Ptch1, which releases 
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Smo by the Ptch1-dependent inhibition. A recent study has demonstrated, by 
examining the effects of Ptch1 overexpression in transgenic mice, that a balance 
between Shh and Ptch1 is necessary for normal brain development (Goodrich, 
Jung et al. 1999). An excess of Ptch1 attenuates the induction of Shh target genes 
and causes abnormal neural tube patterning. This indicates that Ptch1 
overexpression is able to oppose Shh signaling and reveals an important role for 
Ptch1 in brain development and growth. On the contrary, loss-of-function 
mutations or transcriptional repression of Ptch1 leads to constitutive activation of 
Shh signaling pathway and result in an aberrant increase in cell proliferation 
(Izraeli, Lowe et al. 2001). We found that either treatment with SAG, an agonist 
of the Shh pathway that acts downstream to Ptch1 or inhibition of Ptch1 
expression by antisense oligonucleotides, can overcome the mitogenic deficit in 
trisomic NPCs. These results demonstrate that an excess of Ptch1 is the key 
determinant of the reduced transcription of Shh target gene and proliferation 
deficits in trisomic NPCs. The notably increased Ptch1 expression in trisomic 
NPCs explains why Shh levels that were sufficient to activate the pathway in 
euploid NPCs failed to produce a similar effects in trisomic NPCs. Interestingly, 
recent studies have demonstrated that by increasing Shh concentration, it is 
possible to restore the Shh-mitogenic response of trisomic granule cell and 
neuronal crest precursors (Roper, Baxter et al. 2006; Roper, VanHorn et al. 2009). 
This is in line with our findings, because in the presence of an increased number 
of Ptch1 molecules (and hence a strong inhibition of the pathway), a 
corresponding increase in Shh levels is required to activate the pathway in 
trisomic precursor cells. In line with data obtained in NPCs from the Ts65Dn 
mouse model, we found up-regulation of PTCH1 in neuronal precursors of human 
fetuses with DS. Interestingly, a very recent study (Derwinska, Smyk et al. 2009) 
identified PTCH1 duplication in a family with microcephaly and mild 
developmental delay. These patients display many characteristics similar to DS 
such as hypotonia, developmental delay, flat occipit, broad facies, inner epicanthal 
folds, brachydactyly, loose joints, heart defects and delayed myelination. 
According to all this evidence, deregulation of PTCH1 expression may represent a 
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key factor that underlies impairment of neural cell proliferation in individuals 
with DS and, most likely, also different facets of the somatic DS phenotype. 
 
5.4 Mechanisms underlying Ptch1 overexpression in trisomic 
NPCs  
Cleavage of the APP by γ-secretase generates the APP intracellular domain 
(AICD) peptide. Recent evidence shows that AICD is involved in the regulation 
of gene transcription and that PTCH1 is one of the genes that are regulated by 
AICD (Kim, Kim et al. 2004; Muller, Meyer et al. 2008; Raychaudhuri and 
Mukhopadhyay 2010). We found increased levels of AICD in trisomic NPCs, 
which is in agreement with the overexpression of the trisomic gene APP, and an 
increased binding of AICD to the Ptch1 promoter. Inhibition of AICD formation 
reduced the binding of AICD to the Ptch1 promoter and reduced Ptch1 
expression. These findings strongly suggest that AICD overexpression underlies 
Ptch1 up-regulation in trisomic NPCs. It has been recently shown that, in addition 
to genetic mutations in PTCH1 (Evangelista, Tian et al. 2006), epigenetic 
silencing of PTCH1 promoter by DNA methylation and histone deacetylation 
contributes to brain tumor formation (Pritchard and Olson 2008; Ecke, Petry et al. 
2009)). We found that while Ptch1 expression was almost unaffected by 
demethylation (by AZA), it was enhanced by inhibition of deacetylation (by 
TSA), suggesting that acetylation is a major epigenetic mechanism involved in the 
regulation of Ptch1 expression in NPCs. The covalent modification of core 
histones by acetylation leads to a decondensed nucleosomic structure that allows 
access of transcription factors to the DNA (Jenuwein and Allis 2001). The finding 
that in trisomic NPCs, the promoter of Ptch1 was hyper-acethylated suggests that 
this hyper-acetylation may underlie Ptch1 overexpression. AICD has been 
reported to form a complex with Fe65 and the histone acetyltransferase Tip60 and 
cause transcriptional activation by increasing the acetylation status of the 
chromatin (Cao and Sudhof 2001; Kim, Kim et al. 2004). It may, therefore, be 
hypothesized that overproduction of AICD in trisomic NPCs may be involved in 
the hyper-acetylation status of the Ptch1 promoter. Further experiments are 
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needed to clear this issue. 
The role of triplicated genes in the neurological phenotype of DS is still poorly 
understood. Our data suggest that the trisomic gene APP may be a key 
determinant of impaired neurogenesis in DS, through an AICD-dependent up-
regulation of Ptch1 and consequent deregulation of the Shh mitogenic pathway. 
Interestingly, recent evidence shows that AICD transgenic mice exhibit impaired 
neurogenesis similarly to trisomic mice (Ghosal, Stathopoulos et al. 2010). 
APP is cleaved by different secretases, which may result in functionally distinct 
outcomes. The amyloidogenic pathway is initiated by β-secretase cleavage of APP 
to yield the N-terminal soluble APP plus a C-terminal fragment β (CTFβ). CTFβ 
can then be processed by γ-secretase to generate β-amyloid (Aβ) and a free AICD. 
The current study shows a key role of AICD in neurogenesis defects in DS. 
Recent evidence suggests that in addition to Aβ, AICD may be involved in the 
pathogenesis of Alzheimer’s disease. In agreement with APP triplication and, 
hence, increased levels of Aβ and AICD, most individuals with DS develop 
Alzheimer’s disease after the fourth–fifth decade of life. Compounds that inhibit 
or modulate γ-secretase, the pivotal enzyme that generates both Aβ and AICD, 
may be potential therapeutics for the early neurogenesis impairment and late-
occurring neurodegeneration in individuals with DS. 
 
6. CONCLUSION 
All our studies demonstate that proliferation impairment which charaterize the 
trisomic brain, is due to an alteration of the Shh pathway. In particular we show 
that NPcs from Ts65Dn mice exhibit an aberrant overexpression of Ptch-1, Shh 
inhibitory regulator. Ptch-1 overexpression is promoted by a hyperacetilation 
status of its promoter caused by the increades levels of AICD, the APP 
intracellular domain. 
At the same time, NPCs from human fetuses with DS are characterized by an 
overexpression of PTCH1 suggesting that Ptch1 overexpression might 
represent the key determinant of derangement of the Shh pathway and, 
hence, of the reduced proliferation that characterizes the DS brain.
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